0001701541-22-000029.txt : 20220809 0001701541-22-000029.hdr.sgml : 20220809 20220809073104 ACCESSION NUMBER: 0001701541-22-000029 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20220630 FILED AS OF DATE: 20220809 DATE AS OF CHANGE: 20220809 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Black Diamond Therapeutics, Inc. CENTRAL INDEX KEY: 0001701541 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39200 FILM NUMBER: 221146411 BUSINESS ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-417-5868 MAIL ADDRESS: STREET 1: ONE MAIN STREET, 14TH FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aset Therapeutics, Inc. DATE OF NAME CHANGE: 20170321 10-Q 1 bdtx-20220630.htm 10-Q bdtx-20220630
FALSEQ22022000170154112-31http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrentP5YP3YP5Y00017015412022-01-012022-06-3000017015412022-07-28xbrli:shares00017015412022-06-30iso4217:USD00017015412021-12-31iso4217:USDxbrli:shares00017015412022-04-012022-06-3000017015412021-04-012021-06-3000017015412021-01-012021-06-3000017015412020-12-3100017015412021-06-300001701541us-gaap:CommonStockMember2020-12-310001701541us-gaap:AdditionalPaidInCapitalMember2020-12-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001701541us-gaap:RetainedEarningsMember2020-12-310001701541us-gaap:CommonStockMember2021-01-012021-03-310001701541us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-3100017015412021-01-012021-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001701541us-gaap:RetainedEarningsMember2021-01-012021-03-310001701541us-gaap:CommonStockMember2021-03-310001701541us-gaap:AdditionalPaidInCapitalMember2021-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001701541us-gaap:RetainedEarningsMember2021-03-3100017015412021-03-310001701541us-gaap:CommonStockMember2021-04-012021-06-300001701541us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-04-012021-06-300001701541us-gaap:RetainedEarningsMember2021-04-012021-06-300001701541us-gaap:CommonStockMember2021-06-300001701541us-gaap:AdditionalPaidInCapitalMember2021-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300001701541us-gaap:RetainedEarningsMember2021-06-300001701541us-gaap:CommonStockMember2021-12-310001701541us-gaap:AdditionalPaidInCapitalMember2021-12-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001701541us-gaap:RetainedEarningsMember2021-12-310001701541us-gaap:CommonStockMember2022-01-012022-03-310001701541us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-3100017015412022-01-012022-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001701541us-gaap:RetainedEarningsMember2022-01-012022-03-310001701541us-gaap:CommonStockMember2022-03-310001701541us-gaap:AdditionalPaidInCapitalMember2022-03-310001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001701541us-gaap:RetainedEarningsMember2022-03-3100017015412022-03-310001701541us-gaap:CommonStockMember2022-04-012022-06-300001701541us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001701541us-gaap:RetainedEarningsMember2022-04-012022-06-300001701541us-gaap:CommonStockMember2022-06-300001701541us-gaap:AdditionalPaidInCapitalMember2022-06-300001701541us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001701541us-gaap:RetainedEarningsMember2022-06-300001701541srt:MaximumMemberbdtx:OpenMarketSaleMembersrt:ScenarioForecastMember2022-07-012022-09-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:FairValueMeasurementsRecurringMember2022-06-300001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:FairValueMeasurementsRecurringMember2021-12-310001701541us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-06-300001701541us-gaap:CorporateBondSecuritiesMember2022-06-300001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-06-300001701541us-gaap:CorporateBondSecuritiesMember2021-12-310001701541us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-3100017015412021-01-012021-12-310001701541us-gaap:EquipmentMember2022-06-300001701541us-gaap:EquipmentMember2021-12-310001701541us-gaap:FurnitureAndFixturesMember2022-06-300001701541us-gaap:FurnitureAndFixturesMember2021-12-310001701541us-gaap:OfficeEquipmentMember2022-06-300001701541us-gaap:OfficeEquipmentMember2021-12-310001701541us-gaap:LeaseholdImprovementsMember2022-06-300001701541us-gaap:LeaseholdImprovementsMember2021-12-310001701541us-gaap:ConstructionInProgressMember2022-06-300001701541us-gaap:ConstructionInProgressMember2021-12-310001701541bdtx:A2020StockOptionPlanMember2020-01-14xbrli:pure0001701541bdtx:A2020StockOptionPlanMember2022-01-012022-01-010001701541bdtx:A2020StockOptionPlanMember2022-01-010001701541bdtx:A2020EmployeeStockPurchasePlanMember2020-01-140001701541bdtx:A2020EmployeeStockPurchasePlanMember2022-01-012022-01-010001701541us-gaap:EmployeeStockOptionMember2022-04-012022-06-300001701541us-gaap:EmployeeStockOptionMember2021-04-012021-06-300001701541us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001701541us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2022-04-012022-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2021-04-012021-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-06-300001701541bdtx:OtherAwardTypeMember2022-04-012022-06-300001701541bdtx:OtherAwardTypeMember2021-04-012021-06-300001701541bdtx:OtherAwardTypeMember2022-01-012022-06-300001701541bdtx:OtherAwardTypeMember2021-01-012021-06-300001701541us-gaap:EmployeeStockOptionMemberbdtx:A2020StockOptionPlanMember2022-01-012022-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2022-04-012022-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2021-04-012021-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-06-300001701541us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2022-04-012022-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2021-04-012021-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-06-300001701541us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001701541us-gaap:RestrictedStockMember2021-12-310001701541us-gaap:RestrictedStockMember2022-01-012022-06-300001701541us-gaap:RestrictedStockMember2022-06-300001701541us-gaap:RestrictedStockUnitsRSUMember2022-06-300001701541bdtx:PerformanceRestrictedStockUnitsMember2022-01-012022-06-300001701541bdtx:PerformanceRestrictedStockUnitsMember2022-06-300001701541bdtx:A2020EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2022-01-012022-06-300001701541bdtx:A2020EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2022-06-300001701541bdtx:A2020EmployeeStockPurchasePlanMemberus-gaap:EmployeeStockMember2021-01-012021-06-300001701541us-gaap:EmployeeStockOptionMember2022-01-012022-06-300001701541us-gaap:EmployeeStockOptionMember2021-01-012021-06-300001701541us-gaap:RestrictedStockMember2022-01-012022-06-300001701541us-gaap:RestrictedStockMember2021-01-012021-06-300001701541us-gaap:EmployeeStockMember2022-01-012022-06-300001701541us-gaap:EmployeeStockMember2021-01-012021-06-300001701541us-gaap:WarrantMember2022-01-012022-06-300001701541us-gaap:WarrantMember2021-01-012021-06-30bdtx:contract0001701541bdtx:OperatingLeasePrincipalOfficeTwoMember2020-07-31utr:sqft0001701541bdtx:OperatingLeasePrincipalOfficeOneMember2019-02-2800017015412021-06-152021-06-150001701541bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember2020-12-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________________________________
FORM 10-Q
_______________________________________________________________________________
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED June 30, 2022
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM _ TO _
COMMISSION FILE NUMBER 001-38501
___________________________________________
BLACK DIAMOND THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
________________________________________________________________________________
Delaware81-4254660
(State or other jurisdiction
of incorporation or organization)
(I.R.S. Employer
Identification No.)
One Main Street, 14th Floor
Cambridge, Massachusetts
(Address of principal executive offices)
02142
(Zip Code)
(617) 252-0848
(Registrant’s telephone number, including area code)
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001BDTXThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  ☒    No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes  ☒    No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer☐Accelerated filer☐




Non-accelerated filer☒Smaller reporting company☒






Emerging growth company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  ☐    No  ☒
As of July 28, 2022, the registrant had 36,339,466 shares of common stock, $0.0001 par value per share, outstanding.


SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q (this “Quarterly Report”), contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “expects”, “intends”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, “continue” or the negative of these terms or other comparable terminology. These statements are not guarantees of future results or performance and involve substantial risks and uncertainties. Forward-looking statements in this Quarterly Report include, but are not limited to, statements about:
•the progress, timing and success of preclinical studies and our clinical trials of BDTX-1535, BDTX-4933 and any other product candidates, including the availability, timing and announcement of data and results of such studies and trials;
•the initiation, timing, progress and results of our research and development programs, preclinical studies, any clinical trials and Investigational New Drug, or IND, applications and other regulatory submissions;
•the continued development and advancement of our FGFR program and the timing for nominating a development candidate;
•our ability to obtain and maintain regulatory approval for BDTX-1535 and BDTX-4933 or any of our other current or future product candidates that we may identify or develop;
•our need to raise additional funding before we can expect to generate any revenues from product sales;
•our ability to identify future product candidates for treatment of additional disease indications;
•our ability to develop our current product candidates for the treatment of various cancers;
•the rate and degree of market acceptance and clinical utility for any current or future product candidates we may develop;
•the effects of competition with respect to BDTX-1535, BDTX-4933 or any of our other current or future product candidates, as well as innovations by current and future competitors in our industry;
•the implementation of our strategic plans for our business, any product candidates we may develop and our Mutation-Allostery-Pharmacology (“MAP”) drug discovery engine;
•our ability to successfully develop companion diagnostics for use with our current or future product candidates;
•our intellectual property position, including the scope of protection we are able to establish, maintain and enforce for intellectual property rights covering our product candidates and MAP drug discovery engine;
•our ability to obtain additional funding for our operations, when needed, including funding necessary to complete further development and commercialization of our product candidates, if approved, and to further expand our MAP drug discovery engine;
•the period over which we expect our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements;
•the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
•our financial performance and our ability to effectively manage our anticipated growth;
•our estimates regarding the market opportunities for our product candidates, including our competitive position and the success of competing therapies that are or may become available;
2
•our need for and ability to attract and retain key scientific, management and other personnel and to identify, hire and retain additional qualified professionals;
•our ability to establish or maintain collaborations or strategic relationships and the ability and willingness of our third-party strategic collaborators to undertake research and development activities relating to our current or future product candidates;
•our expectations regarding the period during which we will remain an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”);
•our ability to maintain an effective system of internal controls; and
•the ultimate impact of the ongoing coronavirus, or COVID-19 pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole.
Any forward-looking statements in this Quarterly Report reflect our current views with respect to future events and with respect to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. Factors that may cause actual results to differ materially from current expectations include, among other things, those described under Part I, Item 1A, “Risk Factors” and elsewhere in our most recent Annual Report on Form 10-K for the year ended December 31, 2021 (the “Annual Report”) and in other Securities and Exchange Commission (the “SEC”) filings. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.
All of our forward-looking statements are as of the date of this Quarterly Report only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of or any material adverse change in one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the SEC, could materially and adversely affect our business, prospects, financial condition and results of operations. Some of these risks and uncertainties may in the future be amplified by the ongoing COVID-19 pandemic, including as a result of the emergence of new variants, and there may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report that modify or impact any of the forward-looking statements contained in this Quarterly Report will be deemed to modify or supersede such statements in this Quarterly Report.
This Quarterly Report contains summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been filed as exhibits to this Quarterly Report. In this Quarterly Report, the terms “Black Diamond Therapeutics,” “Black Diamond,” the “Company,” “we,” “us,” “our,” and similar designations refer to Black Diamond Therapeutics, Inc. and, where appropriate, our subsidiaries.

3
We may from time to time provide estimates, projections and other information concerning our industry, the general business environment, and the markets for certain diseases, including estimates regarding the potential size of those markets and the estimated incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events, circumstances or numbers, including actual disease prevalence rates and market size, may differ materially from the information reflected in this Quarterly Report. Unless otherwise expressly stated, we obtained this industry, business information, market data, prevalence information and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data, and similar sources, in some cases applying our own assumptions and analysis that may, in the future, prove not to have been accurate.
4
TABLE OF CONTENTS

Page
PART I - FINANCIAL INFORMATION
PART II - OTHER INFORMATION

We have applied for various trademarks that we use in connection with the operation of our business. This Quarterly Report may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties’ trademarks, service marks, trade names or products in this Quarterly Report is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Quarterly Report may appear without the ®, TM or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner of these trademarks, service marks and trade names will not assert, to the fullest extent under applicable law, its rights.
From time to time, we may use our website or our LinkedIn profile at www.linkedin.com/company/black-diamond-therapeutics to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.blackdiamondtherapeutics.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website or our LinkedIn page is not incorporated into, and does not form a part of, this Quarterly Report.

Part I - FINANCIAL INFORMATION
Item I. Condensed Consolidated Financial Statements (Unaudited)
Black Diamond Therapeutics, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share data)

As of

June 30,
2022		December 31,
2021
Assets



Current assets:



Cash and cash equivalents$55,877 

$65,799 
Investments105,013 143,987 
Prepaid expenses and other current assets7,668 

5,917 
Total current assets168,558 

215,703 
Property and equipment, net2,873 

3,035 
Restricted cash1,168 

1,223 
Right-of-use assets26,225 27,705 
Other non-current assets10 

16 
Total assets$198,834 

$247,682 
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable$2,222 

$4,107 
Accrued expenses and other current liabilities17,484 

19,535 
Total current liabilities19,706 

23,642 
Non-current operating lease liabilities26,757 28,140 
Total liabilities46,463 

51,782 
Commitments and contingencies (Note 10)— 

— 
Stockholders' equity:

Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2022 and December 31, 2021; no shares issued or outstanding at June 30, 2022 and December 31, 2021
— — 
Common stock; $0.0001 par value; 500,000,000 shares authorized at June 30, 2022 and December 31, 2021; 36,315,737 shares issued and outstanding at June 30, 2022 and 36,234,624 shares issued and outstanding at December 31, 2021
5 

5 
Additional paid-in capital446,909 

440,129 
Accumulated other comprehensive loss(2,286)(414)
Accumulated deficit(292,257)

(243,820)
Total stockholders' equity152,371 

195,900 
Total liabilities and stockholders' equity$198,834 

$247,682 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share data)

Three Months Ended
June 30,		Six Months Ended
June 30,

2022202120222021
Operating expenses:
Research and development$16,195 $26,719 $33,981 $49,539 
General and administrative6,978 7,996 14,871 15,889 
Total operating expenses23,173 34,715 48,852 65,428 
Loss from operations(23,173)(34,715)(48,852)(65,428)
Other income (expense):
Interest income386 948 792 2,100 
Other (expense) income(143)(584)(377)(1,324)
Total other income (expense), net243 364 415 776 
Net loss$(22,930)$(34,351)$(48,437)$(64,652)
Net loss per share, basic and diluted$(0.63)$(0.95)$(1.33)$(1.79)
Weighted average common shares outstanding, basic and diluted36,293,856 36,182,541 36,282,636 36,152,942 
Comprehensive loss:
Net loss$(22,930)$(34,351)$(48,437)$(64,652)
Other comprehensive income:
Change in unrealized loss on investments(511)(124)(1,872)(403)
Comprehensive loss$(23,441)$(34,475)$(50,309)$(65,055)
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Cash Flows (Unaudited)
(in thousands)
Six Months Ended
June 30,
2022

2021
Cash flows from operating activities:



Net loss$(48,437)$(64,652)
Adjustment to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense6,627 7,652 
Depreciation expense253 39 
Amortization of premium on investments365 1,326 
Noncash rent expense1,371 748 
Other non-cash items— (14)
Loss on disposal of property and equipment3 — 
Changes in current assets and liabilities:
Prepaid expenses and other current assets(1,751)(2,956)
Other non-current assets6 8 
Accounts payable(1,885)1,635 
Accrued expenses and other current liabilities(1,836)7,355 
Non-current operating lease liabilities(1,383)(761)
Net cash used in operating activities(46,667)(49,620)
Cash flows from investing activities:
Purchases of equipment(200)(888)
Proceeds from sales and maturities of investments57,241 95,138 
Purchases of investments(20,504)(42,576)
Net cash provided by investing activities36,537 51,674 
Cash flows from financing activities:
Proceeds from exercise of common stock options and ESPP153 665 
Net cash provided by financing activities153 665 
Net (decrease) increase in cash and cash equivalents(9,977)2,719 
Cash, cash equivalents and restricted cash, beginning of period67,022 35,828 
Cash, cash equivalents and restricted cash, end of period$57,045 $38,547 
Cash and cash equivalents, end of period$55,877 $37,324 
Restricted cash, end of period1,168 1,223 
Cash, cash equivalents and restricted cash, end of period$57,045 $38,547 
Supplemental disclosure of non-cash investing and financing activities:
Purchases of equipment included in accounts payable and accrued expenses $— $1,199 
Right-of-use assets obtained in exchange for operating lease obligation $109 $5,717 
Right-of-use asset derecognized upon early lease termination$— $476 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
8
Black Diamond Therapeutics, Inc.
Condensed Consolidated Statements of Stockholders' Equity (Unaudited)
(in thousands, except share data)

Common stock

Additional
paid-in capital

Accumulated other comprehensive income (loss)Accumulated deficit

Total
stockholders’
equity (deficit)

Shares

Par Value



BALANCE - December 31, 202036,078,383 $5 $425,363 $614 $(118,224)$307,758 
Exercise of common stock options62,607 — 481 — — 481 
Vesting of restricted stock units4,998 — — — — — 
Stock-based compensation1,224 — 3,094 — — 3,094 
Unrealized loss on investments— — — (279)— (279)
Net loss— — — — (30,301)(30,301)
BALANCE - March 31, 202136,147,212 $5 $428,938 $335 $(148,525)$280,753 
Exercise of common stock options48,014 — 184 — — 184 
Vesting of restricted stock units8,331 — — — — — 
Stock-based compensation2,269 — 4,558 — — 4,558 
Unrealized loss on investments— — — (124)— (124)
Net loss— — — — (34,351)(34,351)
BALANCE - June 30, 202136,205,826 $5 $433,680 $211 $(182,876)$251,020 
BALANCE - December 31, 202136,234,624 $5 $440,129 $(414)$(243,820)$195,900 
Exercise of common stock options3,565 — 11 — — 11 
Vesting of restricted stock units5,000 — — — — — 
Issuance of common stock related to ESPP31,341 — 142 — — 142 
Stock-based compensation13,038 — 3,375 — — 3,375 
Unrealized loss on investments— — — (1,361)— (1,361)
Net loss— — — — (25,507)(25,507)
BALANCE - March 31, 202236,287,568 $5 $443,657 $(1,775)$(269,327)$172,560 
Vesting of restricted stock units3,333 — — — — — 
Stock-based compensation24,836 — 3,252 — — 3,252 
Unrealized loss on investments— — — (511)— (511)
Net loss— — — — (22,930)(22,930)
BALANCE - June 30, 202236,315,737 $5 $446,909 $(2,286)$(292,257)$152,371 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
9
Black Diamond Therapeutics, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)
(Amounts in thousands, except share and per share amounts)
1. NATURE OF BUSINESS AND BASIS OF PRESENTATION
Black Diamond Therapeutics, Inc. (the “Company”) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of its mutation, allostery, and pharmacology computational and drug discovery engine.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
On February 1, 2021, the Company filed a shelf registration statement on Form S-3 ASR (the “Shelf”), with the Securities and Exchange Commission (the “SEC”), which covers the offering, issuance and sale of the Company’s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. The Company simultaneously entered into an Open Market Sale AgreementSM with Jefferies LLC, as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies as its sales agent (the “ATM Program”). The Shelf became automatically effective upon filing on February 1, 2021. As of June 30, 2022, no sales have been made pursuant to the ATM Program.
The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred and common stock. The Company expects to continue to generate operating losses for the foreseeable future.
As of August 9, 2022, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.
The Company may seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.
10
The ongoing COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions, and other public health safety measures.
The Company has been closely monitoring the impact of the ongoing COVID-19 pandemic on all aspects of the Company’s business, including how it has impacted and may continue to impact the Company’s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment’s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company’s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company’s third party service providers have also experienced shutdowns or other business disruptions.
The extent to which COVID-19 ultimately impacts the Company’s business, results of operations or financial condition will depend on future developments, which, despite progress in vaccination efforts, remain highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, new strains of the virus, including any future variants that may emerge, which may impact rates of infection and vaccination efforts, developments or perceptions regarding the safety of vaccines, new information that may emerge concerning the severity of COVID-19, and any additional preventative and protective actions taken to contain the pandemic or treat its impact, among others. The Company does not yet know the full extent of potential delays or impacts on the Company’s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions but if the Company or any of the third parties with whom it engages were to experience prolonged business shutdowns or other disruptions, the Company’s ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on the Company’s business, results of operations and financial condition. The estimates of the impact on the Company’s business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.
Principles of consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.
Unaudited interim financial information
The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
11
Use of estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.
Recently issued accounting pronouncements
The Company believes that no recently issued accounting standards will have a material impact on its condensed consolidated financial statements, or apply to its operations.
3. FAIR VALUE MEASUREMENTS
The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

Fair value measurements at June 30, 2022 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$53,761 $— $— $53,761 
Investments:
Commercial paper— 14,542 — 14,542 
Corporate bonds— 51,487 — 51,487 
U.S. Government agencies— 38,984 — 38,984 
Total$53,761 $105,013 $— $158,774 
12

Fair value measurements at December 31, 2021 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$63,730 $— $— $63,730 
Investments:
Corporate bonds— 104,066 — 104,066 
U.S. Government agencies— 39,921 — 39,921 
Total$63,730 $143,987 $— $207,717 
When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument.
There were no transfers in or out of Level 3 categories in the periods presented.
4. INVESTMENTS
As of June 30, 2022, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$14,547 $— $(5)$14,542 
Corporate bonds52,620 — (1,133)51,487 
U.S. Government agencies40,132 — (1,148)38,984 
Total$107,299 $— $(2,286)$105,013 
As of December 31, 2021, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Corporate bonds$104,261 $47 $(242)$104,066 
U.S. Government agencies40,140 — (219)39,921 
Total$144,401 $47 $(461)$143,987 
As of June 30, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $47,880 that had maturities of one to three years.
As of December 31, 2021, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies and corporate bonds with a fair value of $86,187 that had maturities of one to three years.

13
As of June 30, 2022, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $47,880, that had maturities of one to three years. As of December 31, 2021, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies and corporate bonds, with a fair value of $86,187, that had maturities of one to three years.
As of June 30, 2022, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were temporary. In determining whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. There have been no impairments of the Company’s assets measured and carried at fair value during the six months ended June 30, 2022 and the year ended December 31, 2021.
5. PROPERTY AND EQUIPMENT
Property and equipment, net consisted of the following:

June 30,
2022

December 31,
2021
Laboratory equipment$807 $682 
Furniture and fixtures17 17 
Computer and office equipment120 120 
Leasehold improvements2,512 2,437 
Construction in process— 148 
Property and equipment3,456 3,404 
Less: accumulated depreciation(583)(369)
Total Property and Equipment, net$2,873 $3,035 

Depreciation expense for the six months ended June 30, 2022 and 2021 was $253 and $39, respectively.
6. ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued expenses and other current liabilities consisted of the following:

June 30,
2022

December 31,
2021
Contracted research services$11,072 $12,192 
Payroll and related expenses3,352 5,088 
Professional and consulting fees971 1,935 
Current portion of operating lease liability2,089 320 
Total accrued expenses and other current liabilities$17,484 $19,535 


14
7. STOCK-BASED COMPENSATION
2020 Stock Option and Incentive Plan
The 2020 Stock Option and Incentive Plan (the “2020 Plan”) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company’s initial public offering (“IPO”) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, 2022, 1,449,384 shares of common stock, representing 4% of the Company’s outstanding shares of common stock as of December 31, 2021, were added to the 2020 Plan.
2020 Employee Stock Purchase Plan
The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2022.
Stock-based compensation expense
The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2022202120222021
Stock options$3,000 $4,216 $6,193 $7,010 
Restricted stock units189 290 310 560 
Employee Stock Purchase Plan and Other63 52 124 82 

$3,252 $4,558 $6,627 $7,652 
For the six months ended June 30, 2022, the Company issued 37,874 shares of common stock out of its 2020 Plan under its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.
The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2022

202120222021
Research and development$1,526 

$2,234 $3,054 $3,854 
General and administrative1,726 

2,324 3,573 3,798 

$3,252 

$4,558 $6,627 $7,652 
15
Options
The following table summarizes the stock option activity under the Company’s equity awards plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life
(in Years)

Intrinsic
Value
(in thousands)
Outstanding December 31, 20214,903,839 $17.38 7.6$847 
Granted1,816,650 $3.33 
Exercised(3,565)$3.20 
Cancelled or forfeited(691,330)$16.50 
Outstanding June 30, 20226,025,594 $13.25 8.0$289 
Options vested or expected to vest at June 30, 20226,025,594 $13.25 8.0$289 
Options exercisable at June 30, 20222,478,157 $16.05 6.9$45 
For the six months ended June 30, 2022, total unrecognized compensation cost related to the unvested stock-options was $23,832, which is expected to be recognized over a weighted average period of 2.2 years.
Restricted stock units
The fair values of restricted stock units are based on the market value of the Company’s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2022:

Number of
shares
Weighted
average
grant date
fair value
Unvested restricted common stock as of December 31, 202130,667 $29.53 
Granted185,795 $2.32 
Vested(8,333)$29.24 
Unvested restricted common stock as of June 30, 2022208,129 $5.25 
The total fair value of time-based restricted stock units vested during the six months ended June 30, 2022 was $244.
For the six months ended June 30, 2022, total unrecognized compensation cost related to the time-based unvested restricted stock units was $757, which is expected to be recognized over a weighted average period of 1.3 years.
For the three months ended June 30, 2022, the Company granted to its employees 55,125 performance restricted stock units related to the achievement of certain clinical development and/or financing milestones. As of June 30, 2022, the Company had 267,125 performance restricted stock units outstanding.
Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management’s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.
16
As of June 30, 2022, for performance-based restricted stock units that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore no expense has been recognized related to these awards in the six months ended June 30, 2022.
Employee stock purchase plan
The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee’s eligible compensation for each payroll period, up to $25 each calendar year.
During the six months ended June 30, 2022 and 2021, there were 31,341 and no shares, respectively, issued under the 2020 ESPP.
8. NET LOSS PER SHARE
Net loss per share
The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):

Three Months Ended
June 30,		Six Months Ended
June 30,

2022

202120222021
Net loss$(22,930)

$(34,351)$(48,437)$(64,652)
Weighted average common shares outstanding, basic and diluted36,293,856 

36,182,541 36,282,636 36,152,942 
Net loss per share, basic and diluted$(0.63)

$(0.95)$(1.33)$(1.79)

The Company’s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
Six Months Ended
June 30,

20222021
Options to purchase common stock6,025,594 5,209,744 
Unvested restricted stock208,129 51,007 
Shares issuable under employee stock purchase plan27,572 2,940 
Warrants to purchase common stock10,757 10,757 

6,272,052 5,274,448 
17
9. LEASES
The Company has historically entered into lease arrangements for its facilities. As of June 30, 2022, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options.
Operating leases
In July 2020, the Company entered into a seven-year agreement with an option to extend for five additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease.
The Company previously leased an office space in Cambridge, MA under a lease that commenced in February 2019 for approximately 2,357 square feet of office space, which was set to expire on April 30, 2022, subject to an option to extend the lease for three additional years. Effective June 15, 2021, the lease was terminated, and the remaining right-of-use asset and lease liability were derecognized. A gain of $5 was recognized for the termination of the lease.
In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for five additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2022 and 2021:
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Lease Cost
Operating lease cost$1,057 $613 $2,116 $1,075 
Short-term lease cost21 288 40 575 
Variable lease cost219 43 476 76 
Total lease cost$1,297 $944 $2,632 $1,726 
Other Operating Lease InformationJune 30, 2022June 30, 2021
Cash paid for amounts included in the measurement of lease liability$1,290 $732 
Weighted-average remaining lease term8.37.1
Weighted-average discount rate5.3 %5.3 %
The variable lease costs for the three and six months ended June 30, 2022 and 2021 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.
18
Future minimum lease payments under the Company’s operating leases as of June 30, 2022 were as follows:
As of June 30, 2022
2022 (excluding the six months ended June 30, 2022)
$1,460 
20234,244 
20244,359 
20254,477 
20264,599 
Thereafter16,973 
Total lease payments36,112 
Less: interest(7,266)
Total lease liability$28,846 

10. COMMITMENTS AND CONTINGENCIES
The Company enters into contracts in the normal course of business with contract research organizations ("CROs"), contract manufacturing organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.
License agreements
The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of June 30, 2022, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.
Indemnification agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2022 or December 31, 2021.
Legal proceedings
The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.
19
11. BENEFIT PLANS
The Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the “401(k) Plan”). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant’s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). All matching contributions are fully vested when made. During the three and six months ended June 30, 2022 and 2021, the Company contributed $199, $757, $220 and $565, respectively, to the 401(k) Plan.
20
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis should be read in conjunction with the unaudited condensed consolidated financial statements and related notes included elsewhere in this Quarterly Report and our audited consolidated financial statements and related notes thereto for the year ended December 31, 2021, as well as Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 17, 2022. This discussion and analysis and other parts of this Quarterly Report contain forward-looking statements based upon current beliefs, plans and expectations that involve risks, uncertainties and assumptions, such as statements regarding our plans, objectives, expectations, intentions and projections. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth in our Annual Report on Form 10-K and in other SEC filings.
Overview
We are a clinical-stage precision oncology medicine company pioneering the discovery and development of MasterKey therapies. We target undrugged oncogenic driver mutations in patients with genetically defined cancers. The foundation of our company is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. Our proprietary technology platform, which we refer to as our Mutation-Allostery-Pharmacology, or MAP, drug discovery engine, is designed to allow us to analyze population-level genetic sequencing data to discover oncogenic mutations that promote cancer across tumor types. Our goal is to identify families of mutations that can be inhibited with MasterKey therapies thereby providing precision oncology to greater numbers of patients with genetically defined tumors.
We have designed our product candidates to potently and selectively inhibit families of oncogenic mutations which occur across a range of tumor types. BDTX-1535, currently in the dose escalation portion of the ongoing Phase I clinical trial, was designed to inhibit oncogenic mutations in the ErbB-1 epidermal growth factor receptor (EGFR), while sparing normal, or wild type, EGFR (WT-EGFR) activity. The brain penetration properties of BDTX-1535 support the potential treatment of glioblastoma (GBM) and non-small cell lung cancer (NSCLC) patients with or without brain disease. BDTX-4933, currently in IND-enabling studies, was designed to inhibit Class I, II and III canonical and non-canonical mutations. In addition to being a highly selective and potent inhibitor, BDTX-4933 avoids paradoxical activation and is brain penetrant for the treatment of patients with or without brain disease. We are also leveraging our MAP drug discovery engine to identify other families of oncogenic mutations in validated oncogenes, which has the potential to expand the reach of MasterKey therapies. In April 2022, we announced the discontinuation of the development of BDTX-189 to focus on progressing our pipeline through important upcoming milestones for BDTX-1535 and BDTX-4933 as well as discovery efforts.
Since our inception in 2014, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, business planning, raising capital, discovering product candidates and securing related intellectual property rights while conducting research and development activities for our programs. We do not have any products approved for sale and have not generated any revenue from product sales. We may never be able to develop or commercialize a marketable product. We have not yet successfully completed any pivotal clinical trials, obtained any regulatory approvals, manufactured a commercial-scale drug, or conducted sales and marketing activities.
To date, we have funded our operations with proceeds from the sale of preferred stock and common stock. Since inception, we have incurred significant operating losses. Our net losses were $48.4 million and $64.7 million for the six months ended June 30, 2022 and 2021, respectively. As of June 30, 2022, we had an accumulated deficit of $292.3 million. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our current or future product candidates. We expect that our expenses and capital requirements will increase substantially in connection with our ongoing activities, particularly if and as we:
21
•advance clinical studies for BDTX-1535 and continue preclinical studies for BDTX-4933 and our other product candidates;
•continue to identify additional product candidates from our proprietary MAP drug discovery engine;
•obtain, maintain, expand and protect our intellectual property portfolio;
•attract and retain key clinical, scientific, management and commercial personnel;
•seek marketing approvals for our product candidates that successfully complete clinical trials, if any; and
•acquire or in-license additional product candidates.
As a result, we will need substantial additional funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, which may include collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential in-licenses or acquisitions.
Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.
As of June 30, 2022, we had cash, cash equivalents and investments of approximately $160.9 million, which we believe will fund our operating expenses and capital expenditure requirements into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See “—Liquidity and capital resources.” To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives.
COVID-19 considerations
The ongoing COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions, and other public health safety measures.
The Company has been closely monitoring the impact of the ongoing COVID-19 pandemic on all aspects of the Company’s business, including how it has impacted and may continue to impact the Company’s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment’s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company’s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company’s third party service providers have also experienced shutdowns or other business disruptions.
The extent to which COVID-19 ultimately impacts the Company’s business, results of operations or financial condition will depend on future developments, which, despite progress in vaccination efforts, remain highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, new strains of the virus, including any future variants that may emerge, which may impact rates of infection and vaccination efforts,
22
developments or perceptions regarding the safety of vaccines, new information that may emerge concerning the severity of COVID-19, and any additional preventative and protective actions taken to contain the pandemic or treat its impact, among others. The Company does not yet know the full extent of potential delays or impacts on the Company’s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions but if the Company or any of the third parties with whom it engages were to experience prolonged business shutdowns or other disruptions, the Company’s ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on the Company’s business, results of operations and financial condition. The estimates of the impact on the Company’s business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.
Additionally, inflation generally affects the Company by increasing its employee-related costs and clinical trial expenses, as well as other operating expenses. The Company’s financial condition and results of operations may also be impacted by other factors it may not be able to control, such as global supply chain disruptions, global trade disputes or political instability.
Components of our results of operations
Revenue
To date, we have not generated any revenue from any sources, including from product sales, and we do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for our product candidates are successful and result in regulatory approval, or license agreements with third parties, we may generate revenue in the future from product sales. However, there can be no assurance as to when we will generate such revenue, if at all.
Operating expenses
Research and development expenses
Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts and the development of our product candidates. We expense research and development costs as incurred, which include:
•expenses incurred to conduct the necessary preclinical studies and clinical trials required to obtain regulatory approval;
•expenses incurred under agreements with contract research organizations, or CROs, that are primarily engaged in the oversight and conduct of our drug discovery efforts and preclinical studies, clinical trials and contract manufacturing organizations, or CMOs, that are primarily engaged to provide preclinical and clinical drug substance and product for our research and development programs;
•other costs related to acquiring and manufacturing materials in connection with our drug discovery efforts and preclinical studies and clinical trial materials, including manufacturing validation batches, as well as investigative sites and consultants that conduct our clinical trials, preclinical studies and other scientific development services;
•payments made in cash or equity securities under third-party licensing, acquisition and option agreements;
•employee-related expenses, including salaries and benefits, travel and stock-based compensation expense for employees engaged in research and development functions;
•costs related to compliance with regulatory requirements; and
•allocated facilities-related costs, depreciation and other expenses, which include rent and utilities.
23
We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our service providers. This process involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. Any nonrefundable advance payments that we make for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. Such amounts are expensed as the related goods are delivered or the related services are performed, or until it is no longer expected that the goods will be delivered or the services rendered.
Our direct external research and development expenses consist primarily of external costs, such as fees paid to outside consultants, CROs, CMOs and research laboratories in connection with our preclinical development, process development, manufacturing and clinical development activities. Our direct research and development expenses also include fees incurred under license, acquisition and option agreements. We do not allocate employee costs, costs associated with our discovery efforts, laboratory supplies, and facilities, including depreciation or other indirect costs, to specific programs because these costs are deployed across multiple programs and, as such, are not separately classified. We use internal resources primarily to conduct our research and discovery as well as for managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across multiple programs and, therefore, we do not track their costs by program.
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially over the next several years as we continue our clinical trials for BDTX-1535, as well as conduct other preclinical and clinical development, including submitting regulatory filings for other product candidates.
We expect our discovery research efforts and our related personnel costs will increase and, as a result, we expect our research and development expenses, including costs associated with stock-based compensation, will increase above historical levels. In addition, we may incur additional expenses related to milestone and royalty payments payable to third parties with whom we may enter into license, acquisition and option agreements to acquire the rights to future product candidates.
At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical and clinical development of any of our product candidates or when, if ever, material net cash inflows may commence from any of our product candidates. The successful development and commercialization of our product candidates is highly uncertain. This uncertainty is due to the numerous risks and uncertainties associated with product development and commercialization, including the uncertainty of the following:
•the scope, progress, outcome and costs of our preclinical development activities, clinical trials and other research and development activities;
•establishing an appropriate safety and efficacy profile with IND-enabling studies;
•successful patient enrollment in and the initiation and completion of clinical trials;
•the timing, receipt and terms of any marketing approvals from applicable regulatory authorities including the U.S. Food and Drug Administration, or the FDA, and non-U.S. regulators;
•the extent of any required post-marketing approval commitments to applicable regulatory authorities;
•establishing clinical and commercial manufacturing capabilities or making arrangements with third-party manufacturers in order to ensure that we or our third-party manufacturers are able to make product successfully;
•development and timely delivery of clinical-grade and commercial-grade drug formulations that can be used in our clinical trials and for commercial launch;
•obtaining, maintaining, defending and enforcing patent claims and other intellectual property rights;
24
•significant and changing government regulation;
•launching commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; and
•maintaining a continued acceptable safety profile of our product candidates following approval, if any, of our product candidates.
Any changes in the outcome of any of these variables with respect to the development of our product candidates in preclinical and clinical development could mean a significant change in the costs and timing associated with the development of these product candidates. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those that we currently expect or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development of that product candidate.
General and administrative expenses
General and administrative expenses consist primarily of salaries and benefits, travel and stock-based compensation expense for personnel in executive, business development, finance, human resources, legal, information technology, pre-commercial and support personnel functions. General and administrative expenses also include direct and allocated facility-related costs as well as insurance costs and professional fees for legal, patent, consulting, investor and public relations, accounting and audit services.
We anticipate that our general and administrative expenses will increase in the future as we increase our headcount to support our continued research activities and development of our product candidates and prepare for potential commercialization activities. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and other employee-related expenses as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of that product candidate.
Other income (expense)
Other income (expense) consists primarily of interest income earned on our cash equivalents and investment balances, and realized and unrealized foreign currency transaction gains and losses.
25
Results of operations
Comparison of the three months ended June 30, 2022 and 2021
The following table summarizes our results of operations for the three months ended June 30, 2022 and 2021:

Three Months Ended
June 30,



2022

2021

Change

(in thousands)
Operating expenses:
Research and development$16,195 $26,719 $(10,524)
General and administrative6,978 7,996 (1,018)
Total operating expenses23,173 34,715 (11,542)
Loss from operations(23,173)(34,715)11,542 
Other income (expense):
Interest income386 948 (562)
Other (expense) income(143)(584)441 
Total other income (expense), net243 364 (121)
Net loss$(22,930)$(34,351)$11,421 
Research and development
Research and development expenses were $16.2 million for the three months ended June 30, 2022, compared to $26.7 million for the three months ended June 30, 2021. The following table summarizes our research and development expenses for the three months ended June 30, 2022 and 2021:

Three Months Ended
June 30,



2022

2021

Change

(in thousands)
BDTX-189 research and development expenses$2,561 $7,369 $(4,808)
BDTX-1535 research and development expenses1,089 1,822 (733)
Other research programs and platform development expenses5,189 9,334 (4,145)
Personnel expenses5,968 7,122 (1,154)
Allocated facility expenses974 840 134 
Other expenses414 232 182 
$16,195 $26,719 $(10,524)
The decrease of $10.5 million for the three months ended June 30, 2022 was primarily due to a decrease of $4.8 million in spend relating to BDTX-189 associated with reduced trial activities stemming from the discontinuation of the development of BDTX-189 to focus on upcoming milestones for our pipeline programs, BDTX-1535 and BDTX-4933. In addition, we decreased spend relating to other research programs and platform development by $4.1 million for the three months ended June 30, 2022 due to reduced spending on early discovery projects, compared to the three months ended June 30, 2021.
26
General and administrative
General and administrative expenses were $7.0 million for the three months ended June 30, 2022 compared to $8.0 million for the three months ended June 30, 2021. This was primarily a result of flat personnel-related costs and a decrease in legal and other professional fees.
Other income (expense)
Other income was $0.2 million for the three months ended June 30, 2022, compared to $0.4 million for the three months ended June 30, 2021. The decrease was primarily attributable to amortization of premium on investments decreasing at a higher rate in 2022 compared to 2021 and interest income decreasing due to market conditions.
Comparison of the six months ended June 30, 2022 and 2021
The following table summarizes our results of operations for the six months ended June 30, 2022 and 2021:

Six Months Ended
June 30,



2022

2021

Change

(in thousands)
Operating expenses:
Research and development$33,981 $49,539 $(15,558)
General and administrative14,871 15,889 (1,018)
Total operating expenses48,852 65,428 (16,576)
Loss from operations(48,852)(65,428)16,576 
Other income (expense):
Interest income792 2,100 (1,308)
Other (expense) income(377)(1,324)947 
Total other income (expense), net415 776 (361)
Net loss$(48,437)$(64,652)$16,215 
Research and development
Research and development expenses were $34.0 million for the six months ended June 30, 2022, compared to $49.5 million for the six months ended June 30, 2021. The following table summarizes our research and development expenses for the six months ended June 30, 2022 and 2021:

Six Months Ended
June 30,



2022

2021

Change

(in thousands)
BDTX-189 research and development expenses$5,044 $15,487 $(10,443)
BDTX-1535 research and development expenses2,477 2,447 30 
Other research programs and platform development expenses10,722 17,229 (6,507)
Personnel expenses12,905 12,710 195 
Allocated facility expenses2,005 1,348 657 
Other expenses828 318 510 
$33,981 $49,539 $(15,558)
27
The decrease of $15.6 million in the six months ended June 30, 2022 was primarily due to a decrease of $10.4 million in spend relating to BDTX-189 associated with reduced trial activities stemming from the discontinuation of the development of BDTX-189 to focus on upcoming milestones for our pipeline programs, BDTX-1535 and BDTX-4933. In addition, we decreased spend relating to other research programs and platform development by $6.5 million for the six months ended June 30, 2022 due to reduced spending on early discovery projects, compared to the six months ended June 30, 2021. Facility costs increased $0.7 million for the six months ended June 30, 2022, compared to the six months ended June 30, 2021 due to the signing of a new lease.
General and administrative
General and administrative expenses were $14.9 million for the six months ended June 30, 2022, compared to $15.9 million for the six months ended June 30, 2021. This was primarily a result of flat personnel-related costs and a decrease in legal and other professional fees.
Other income (expense)
Other income was $0.4 million for the six months ended June 30, 2022, compared to $0.8 million for the six months ended June 30, 2021. The decrease was primarily attributable to amortization of premium on investments decreasing at a higher rate in 2022 compared to 2021 and interest income decreasing due to market conditions.
Liquidity and capital resources
Sources of liquidity
Since our inception, we have not generated any revenue from any product sales or any other sources and have incurred significant operating losses and negative cash flows from our operations. We have not yet commercialized any of our product candidates, and we do not expect to generate revenue from sales of any product candidates for several years, if at all. We have funded our operations to date primarily with proceeds from the sale of preferred stock. On February 3, 2020, we completed an IPO of 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, for aggregate gross proceeds of $231.3 million. We received $212.1 million in net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. Through June 30, 2022, we had received net cash proceeds of $200.6 million from previous sales of our preferred stock and as of June 30, 2022, we had cash, cash equivalents and investments of $160.9 million.
Cash flows
The following table summarizes our sources and uses of cash for each of the periods presented (in thousands):

Six Months Ended
June 30,

2022

2021
Cash used in operating activities$(46,667)

$(49,620)
Cash provided by investing activities
36,537 

51,674 
Cash provided by financing activities
153 

665 
Net (decrease) increase in cash and cash equivalents
$(9,977)

$2,719 
Operating activities
During the six months ended June 30, 2022, we used cash in operating activities of $46.7 million, primarily resulting from our net loss of $48.4 million, partially offset by the non-cash charge related to stock compensation expense of $6.6 million.
28
During the six months ended June 30, 2021, we used cash in operating activities of $49.6 million, primarily resulting from our net loss of $64.7 million, partially offset by the non-cash charge related to stock compensation expense of $7.7 million and an increase in prepaid expenses and other current assets.
Changes in accounts payable and accrued expenses in all periods were generally due to growth in our business, the advancement of our product candidates, and the timing of vendor invoicing and payments.
Investing activities
During the six months ended June 30, 2022, we had cash provided by investing activities of $36.5 million primarily from the sales and maturities of investments.
During the six months ended June 30, 2021, we had cash provided by investing activities of $51.7 million primarily from the sales and maturities of investments.
Financing activities
During the six months ended June 30, 2022, we had cash provided by financing activities of $0.2 million, consisting of proceeds from exercise of stock options and participation in the employee stock purchase plan.
During the six months ended June 30, 2021, we had cash provided by financing activities of $0.7 million consisting of proceeds from exercise of stock options.
Funding requirements
We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, we expect to incur additional costs associated with operating as a public company, including significant legal, accounting, investor relations and other expenses. The timing and amount of our operating expenditures will depend largely on our ability to:
•advance BDTX-1535 through clinical trials and continue preclinical studies for BDTX-4933;
•advance preclinical development of our early stage programs, including our FGFR program, including plans for nominating a development candidate;
•manufacture, or have manufactured on our behalf, our preclinical and clinical drug material and develop processes for late state and commercial manufacturing;
•seek regulatory approvals for any product candidates that successfully complete clinical trials;
•establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize on our own;
•hire additional clinical, quality control and scientific personnel; and
•obtain, maintain, expand and protect our intellectual property portfolio.
As of June 30, 2022, we had cash, cash equivalents and investments of $160.9 million, which we believe will fund our operating expenses and capital expenditure requirements into the third quarter of 2024. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we expect. We anticipate that we will require additional capital as we seek regulatory approval of our product candidates and if we choose to pursue in-licenses or acquisitions of other product candidates. If we receive regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, sales, marketing and distribution, depending on where we choose to commercialize.
Because of the numerous risks and uncertainties associated with research, development and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements. Our future funding requirements will depend on and could increase significantly as a result of many factors, including:
29
•the scope, progress, results and costs of researching and developing our product candidates, and conducting preclinical and clinical trials;
•the costs, timing and outcome of regulatory review of our product candidates;
•the costs, timing and ability to manufacture our product candidates to supply our clinical and preclinical development efforts and our clinical trials;
•the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution, for any of our product candidates for which we receive marketing approval;
•the costs of manufacturing commercial-grade product and necessary inventory to support commercial launch;
•the ability to receive additional non-dilutive funding;
•the revenue, if any, received from commercial sale of our products, should any of our product candidates receive marketing approval;
•the costs of preparing, filing and prosecuting patent applications, obtaining, maintaining, expanding and enforcing our intellectual property rights and defending intellectual property-related claims;
•our ability to establish and maintain collaborations on favorable terms, if at all; and
•the extent to which we acquire or in-license other product candidates and technologies.
Until such time, if ever, as we can generate substantial product revenue, we expect to finance our operations through a combination of public or private equity offerings, debt financings, collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest may be materially diluted, and the terms of such securities could include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing and preferred equity financing, if available, may involve agreements that include restrictive covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. In addition, debt financing would result in fixed payment obligations.
If we raise additional funds through collaborations, strategic partnerships and alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings or other arrangements when needed, we may be required to delay, limit, reduce or terminate our research, product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.
Contractual obligations and commitments
The following summarizes our contractual obligations as of June 30, 2022:

Payments Due by Period

Less than 1 Year1 to 3 Years3 to 5 YearsMore than 5 Years

Total
(in thousands)
Property leases - commenced
$3,562 $8,718 $9,199 $14,633 $36,112 
Total
$3,562 $8,718 $9,199 $14,633 

$36,112 
30
Property leases – commenced
The amounts reported for property leases represent future minimum lease payments under non-cancelable operating leases in effect as of June 30, 2022. The minimum lease payments do not include common area maintenance charges or real estate taxes.
Other contractual obligations
The contractual obligations table does not include any potential future milestone payments or royalty payments we may be required to make under our existing license agreements due to the uncertainty of the occurrence of the events requiring payment under those agreements.
Critical accounting policies and significant judgments and use of estimates
Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations— Critical Accounting Policies and Use of Estimates” in our Annual Report on Form 10-K for the year ended December 31, 2021, which was filed with the SEC on March 17, 2022. During the six months ended June 30, 2022, there were no material changes to our critical accounting policies from those previously disclosed.
Recently issued accounting pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in Note 2 to our condensed consolidated financial statements appearing elsewhere in this Quarterly Report.
Emerging growth company and smaller reporting company status
The Jumpstart Our Business Startups Act of 2012 permits an “emerging growth company” such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have elected to not “opt out” of this provision and, as a result, we will adopt new or revised accounting standards at the time private companies adopt the new or revised accounting standard and will do so until such time that we either (i) irrevocably elect to “opt out” of such extended transition period or (ii) no longer qualify as an emerging growth company.
We are also a “smaller reporting company” meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.
31
Item 3. Quantitative and Qualitative Disclosure About Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.
Item 4. Controls and Procedures
Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Interim Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and Interim Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2022.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) that occurred during the period covered by this Quarterly Report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
32
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
The information required with respect to this item can be found under “Legal Proceedings” in Note 10 to our condensed financial statements included elsewhere in this Quarterly Report on Form 10-Q and is incorporated by reference into this Item 1. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business, the resolution of which we do not anticipate would have, individually or in the aggregate, a material adverse effect on our business, financial condition or results of operations.
Item 1A. Risk Factors
Our business faces significant risks and uncertainties. Certain important factors may have a material adverse effect on our business prospects, financial condition and results of operations, and you should carefully consider them. Accordingly, in evaluating our business, we encourage you to carefully consider the discussion of risk factors in Part I, “Item 1A. Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2021, which could materially affect our business, financial condition or future results, in addition to other information contained in or incorporated by reference into this Quarterly Report on Form 10-Q and our other public filings with the Securities and Exchange Commission, or the SEC. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business, prospects, financial condition and results of operations. Certain statements in this Quarterly Report are forward-looking statements. Please also see the section entitled “Special Note Regarding Forward-Looking Statements.”
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Recent Sales of Unregistered Equity Securities
None.
Use of Proceeds from IPO of Common Stock
On February 3, 2020, we completed the IPO of our common stock pursuant to which we issued and sold 12,174,263 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to 1,587,947 additional shares of common stock, at a public offering price of $19.00 per share.
The offer and sale of all of the shares of our common stock in our IPO were registered under the Securities Act pursuant to a registration statement on Form S-1, as amended (File No. 333-235789), which was declared effective by the SEC on January 29, 2020. J.P. Morgan Securities LLC, Jefferies LLC, Cowen and Company, LLC and Canaccord Genuity LLC acted as joint book-running managers of the offering and as representatives of the underwriters.
We received aggregate gross proceeds from our IPO of $231.3 million, or aggregate net proceeds of $212.1 million after deducting underwriting discounts and commissions and other offering costs. None of the underwriting discounts and commissions or offering expenses were incurred or paid, directly or indirectly, to any of our directors or officers or their associates or to persons owning 10% or more of our common stock or to any of our affiliates.

There has been no material change in our planned use of the net proceeds from the IPO as described in our final prospectus, filed with the SEC pursuant to Rule 424(b)(4) under the Securities Act on January 30, 2020.
Item 3. Defaults Upon Senior Securities
None.
33
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
Not applicable.
34

Item 6. Exhibits
The exhibits listed on the Exhibit Index immediately preceding such exhibits, which is incorporated herein by reference, are filed or furnished as part of this Quarterly Report.
Exhibit
No.

Exhibit Index
10.1#*
31.1*
31.2*
32.1*+
101.INS

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH

Inline XBRL Taxonomy Extension Schema Document.
101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB

Inline XBRL Taxonomy Extension Labels Linkbase Document.
101.PRE

Inline XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document.
104Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.)
*

Filed herewith.
#Indicates a management contract or any compensatory plan, contract or arrangement.
+

This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.

35
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Black Diamond Therapeutics, Inc.



Date: August 9, 2022By:
/s/ David M. Epstein


David M. Epstein
President and Chief Executive Officer
(Principal Executive Officer)

Black Diamond Therapeutics, Inc.



Date: August 9, 2022By:
/s/ Fang Ni


Fang Ni
Chief Business and Interim Chief Financial Officer
(Principal Financial Officer)

36
 EX-10.1 2 blackdiamond-executiveempl.htm EX-10.1 Document

EMPLOYMENT AGREEMENT
This Employment Agreement (“Agreement”) is made between Black Diamond Therapeutics, Inc., a Delaware corporation (the “Company”), and Sergey Yurasov, M.D., Ph.D. (the “Executive”) and is effective as of June 1, 2022 (the “Effective Date”). This Agreement supersedes in all respects all prior agreements between the Executive and the Company regarding the subject matter herein, including without limitation the offer letter between the Executive and the Company dated April 29, 2022 (the “Prior Agreement”).
WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company on the terms and conditions contained herein.
NOW, THEREFORE, in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:
1.Employment.
(a)Term. The Company shall employ the Executive and the Executive shall be employed by the Company pursuant to this Agreement commencing as of the Effective Date and continuing until such employment is terminated in accordance with the provisions hereof (the “Term”). The Executive’s employment with the Company will be “at will,” meaning that the Executive’s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement.
(b)Position and Duties. The Executive shall serve as the Chief Medical Officer of the Company based in San Francisco, California, and shall have such powers and duties as may from time to time be prescribed by the CEO or other duly authorized executive. The Executive shall devote the Executive’s full working time and efforts to the business and affairs of the Company. Notwithstanding the foregoing, the Executive may (1) serve on other boards of directors, with the approval of the Board of Directors of the Company (the “Board”), or engage in religious, charitable or other community activities as long as such services and activities are disclosed to the Board and do not interfere with the Executive’s performance of the Executive’s duties to the Company and (2) provide consulting services to third parties with the prior approval of the CEO, as long as such services do not interfere with the Executive’s performance of the Executive’s duties to the Company or represent a conflict of interest. To the extent applicable, the Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive’s employment for any reason. The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.
2.Compensation and Related Matters.
(c)Base Salary. The Executive’s initial base salary shall be paid at the rate of $465,000 per year. The Executive’s base salary shall be subject to periodic review by the Board or the Compensation Committee of the Board (the “Compensation Committee”). The base salary in effect at any given time is referred to herein as “Base Salary.” The Base Salary shall be payable in a manner that is consistent with the Company’s usual payroll practices for executive officers.
(d)Incentive Compensation. The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time. The Executive’s initial target annual incentive compensation shall be 40 percent of the
1

Executive’s Base Salary; provided that any incentive compensation awarded with respect to calendar year 2022 will be pro-rated for the number of months in 2022 of full-time employment with the Company. The target annual incentive compensation in effect at any given time is referred to herein as “Target Bonus.” The actual amount of the Executive’s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time. Except as otherwise provided herein, to earn incentive compensation, the Executive must be employed by the Company on the day such incentive compensation is paid.
(e)Signing Bonus. The Executive will be eligible to receive a signing bonus in the gross amount of $77,500, less applicable taxes and withholdings (the “Signing Bonus”), which will be paid in two equal installments in the gross amount of $ 38,750 each. The first installment of the Signing Bonus will be paid in the second pay period following the Effective Date, provided that the Executive remains employed as of the date of payment. The second and final installment of the Signing Bonus will be paid in the first pay period following the six month anniversary of the Effective Date, provided that the Executive remains employed as of the date of payment.
(f)Expenses. The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers.
(g)Corporate Housing. During the first six months of employment with the Company, the Company will provide the Executive housing reachable by walking and/or public transportation from the Company’s office in Cambridge, Massachusetts, at a cost of up to $5000 per month, and the Company will take steps to ensure that the income tax impact for the Executive shall be approximately tax neutral.
(h)Other Benefits. The Executive shall be eligible to participate in or receive benefits under the Company’s employee benefit plans in effect from time to time, subject to the terms of such plans.
(i)Paid Time Off. The Executive shall be entitled to take paid time off in accordance with the Company’s applicable paid time off policy for executives, as may be in effect from time to time.
(j)Equity. In connection with the commencement of the Executive’s employment and subject to Board approval, the Executive will be granted an option to purchase 250,000 shares of the Company’s common stock subject to time-based vesting, with an exercise price equal to the fair market value of the Company’s common stock as of the date of such grant. One quarter of such shares shall vest when the Executive completes 12 months of service after the vesting commencement date, and 1/48th of such shares shall vest each month thereafter, subject to the Executive’s continued service at each vesting date. The equity awards described in this Section 2(h) shall be governed by the terms and conditions of the Company’s applicable equity incentive plan(s) and the applicable award agreement(s) governing the terms of such equity awards (collectively, the “Equity Documents”); provided, however, and notwithstanding anything to the contrary in the Equity Documents, Section 6(a)(ii) of this Agreement shall apply in the event of a termination by the Company without Cause or by the Executive for Good Reason in either event within the Change in Control Period (as such terms are defined below).
3.Termination. The Executive’s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:
2

(k)Death. The Executive’s employment hereunder shall terminate upon death.
(l)Disability. The Company may terminate the Executive’s employment if the Executive is disabled and unable to perform the essential functions of the Executive’s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period. If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive’s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive’s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue. The Executive shall cooperate with any reasonable request of the physician in connection with such certification. If such question shall arise and the Executive shall fail to submit such certification, the Company’s determination of such issue shall be binding on the Executive. Nothing in this Section 3(b) shall be construed to waive the Executive’s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. §2601 et seq. and the Americans with Disabilities Act, 42 U.S.C. §12101 et seq.
(m)Termination by Company for Cause. The Company may terminate the Executive’s employment hereunder for Cause. For purposes of this Agreement, “Cause” shall mean any of the following:
(i)the willful failure, disregard or refusal by the Executive to perform the Executive’s material duties or obligations under this Agreement which, to the extent it is curable by the Executive, is not cured within thirty (30) days after written notice thereof is given to the Executive by the Company;
(ii)any willful, intentional or grossly negligent act by the Executive having the effect of materially injuring (whether financially or otherwise) the business or reputation of the Company or any of its affiliates, including but not limited to, any senior officer, director or executive of the Company or any of its affiliates;
(iii)willful misconduct by the Executive with respect to any of the material duties or obligations of the Executive under this Agreement, including, without limitation, willful insubordination with respect to lawful directions received by the Executive from the Board which, to the extent it is curable by the Executive, is not cured within thirty (30) days after written notice thereof is given to the Executive by the Company;
(iv)the commission by the Executive of acts satisfying the elements of (A) any felony or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud;
(v)the determination, after a reasonable and good-faith investigation by the Company, that the Executive engaged in some form of harassment or discrimination prohibited by law (including, without limitation, age, sex or race harassment or discrimination);
(vi)the Executive’s material misappropriation or embezzlement of the property of the Company or its affiliates (whether or not a misdemeanor or felony);
3

(vii)material breach by the Executive of any of the provisions of this Agreement, of any Company policy, and/or of the Executive’s Restrictive Covenants Agreement (as defined below); or
(viii)the Executive’s failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.
(n)Termination by the Company without Cause. The Company may terminate the Executive’s employment hereunder at any time without Cause. Any termination by the Company of the Executive’s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.
(o)Termination by the Executive. The Executive may terminate employment hereunder at any time for any reason, including but not limited to, Good Reason. For purposes of this Agreement, “Good Reason” shall mean that the Executive has completed all steps of the Good Reason Process (hereinafter defined) following the occurrence of any of the following events without the Executive’s consent (each, a “Good Reason Condition”):
(i)a material adverse change in Executive’s duties, authority, responsibilities or reporting chain relative to Executive’s duties, authority, or responsibilities in effect immediately prior to such change;
(ii)a material diminution in the Executive’s Base Salary except for across-the-board salary reductions based on the Company’s financial performance similarly affecting all or substantially all senior management employees of the Company;
(iii)a material change in the geographic location at which the Executive provides services to the Company, such that there is an increase of at least thirty (30) miles of driving distance to such location from the Executive’s principal residence as of such change; or
(iv)a material breach of this Agreement by the Company.
The “Good Reason Process” consists of the following steps:
(i)the Executive reasonably determines in good faith that a Good Reason Condition has occurred;
(ix)the Executive notifies the Company in writing of the first occurrence of the Good Reason Condition within 60 days of the first occurrence of such condition;
(x)the Executive cooperates in good faith with the Company’s efforts, for a period of not less than 30 days following such notice (the “Cure Period”), to remedy the Good Reason Condition;
(xi)notwithstanding such efforts, the Good Reason Condition continues to exist; and
4

(xii)the Executive terminates employment within 60 days after the end of the Cure Period.
If the Company cures the Good Reason Condition during the Cure Period, Good Reason shall be deemed not to have occurred.
If the Executive’s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to the Executive’s authorized representative or estate) (i) any Base Salary earned through the Date of Termination; (ii) unpaid expense reimbursements (subject to, and in accordance with, Section 2(d) of this Agreement); and (iii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the “Accrued Obligations”).
4.Notice and Date of Termination.
(a)Notice of Termination. Except for termination as specified in Section 3(a), any termination of the Executive’s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto. For purposes of this Agreement, a “Notice of Termination” shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.
(b)Date of Termination. “Date of Termination” shall mean: (i) if the Executive’s employment is terminated by death, the date of death; (ii) if the Executive’s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive’s employment is terminated by the Company without Cause under Section 3(d), the date on which a Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination; (iv) if the Executive’s employment is terminated by the Executive under Section 3(e) other than for Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive’s employment is terminated by the Executive under Section 3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period. Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.
5.Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period. If the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d), or the Executive terminates employment for Good Reason as provided in Section 3(e), each outside of the Change in Control Period (as defined below), then, in addition to the Accrued Obligations, and subject to (i) the Executive signing a separation agreement and release in a form and manner satisfactory to the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities, a reaffirmation of all of the Executive’s Continuing Obligations (as defined below), and shall provide that if the Executive breaches any of the Continuing Obligations, all payments of the Severance Amount shall immediately cease (the “Separation Agreement and Release”), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), which shall include a seven (7) business day revocation period:
5

(a)the Company shall pay the Executive an amount equal to the sum of (A) 12 months of the Executive’s Base Salary plus (B) the Executive’s Target Bonus for the thencurrent year (the “Severance Amount”);and
(b)subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall pay to the group health plan provider, the COBRA provider or the Executive a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the 12 month anniversary of the Date of Termination; (B) the Executive’s eligibility for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s continuation rights under COBRA; provided, however, if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.
The amounts payable under Section 5, to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company’s payroll practice over 12 months commencing within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount, to the extent it qualifies as “non-qualified deferred compensation” within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”), shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).
6.Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in Control Period. The provisions of this Section 6 shall apply in lieu of, and expressly supersede, the provisions of Section 5 if (i) the Executive’s employment is terminated either (a) by the Company without Cause as provided in Section 3(d), or (b) by the Executive for Good Reason as provided in Section 3(e), and (ii) the Date of Termination is within 12 months after the occurrence of the first event constituting a Change in Control (such period, the “Change in Control Period”). These provisions shall terminate and be of no further force or effect after a Change in Control Period.
(c)If the Executive’s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates employment for Good Reason as provided in Section 3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release becoming fully effective, all within the time frame set forth in the Separation Agreement and Release but in no event more than 60 days after the Date of Termination:
(i)the Company shall pay the Executive a lump sum in cash in an amount equal to 1.0 times the sum of (A) the Executive’s then current Base Salary (or the Executive’s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) the Executive’s Target Bonus for the then-current year (the “Change in Control Payment”); and
6

(ii)notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all stock options and other stock-based awards held by the Executive (the “Equity Awards”) shall immediately accelerate and become fully exercisable or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release (the “Accelerated Vesting Date”); provided that any termination or forfeiture of the unvested portion of such Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth therein. Notwithstanding the foregoing, no additional vesting of the Equity Awards shall occur during the period between the Executive’s Date of Termination and the Accelerated Vesting Date; and
(iii)subject to the Executive’s copayment of premium amounts at the applicable active employees’ rate and the Executive’s proper election to receive benefits under COBRA, the Company shall pay to the group health plan provider, the COBRA provider or the Executive a monthly payment equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive if the Executive had remained employed by the Company until the earliest of (A) the 12 month anniversary of the Date of Termination; (B) the Executive’s eligibility for group medical plan benefits under any other employer’s group medical plan; or (C) the cessation of the Executive’s continuation rights under COBRA; provided, however, if the Company determines that it cannot pay such amounts to the group health plan provider or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payroll payments directly to the Executive for the time period specified above. Such payments shall be subject to tax-related deductions and withholdings and paid on the Company’s regular payroll dates.
The amounts payable under this Section 6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as “non-qualified deferred compensation” within the meaning of Section 409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.
(a)Additional Limitation.
(iv)Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code, and the applicable regulations thereunder (the “Aggregate Payments”), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction. In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (1) cash
7

payments not subject to Section 409A of the Code; (2) cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. §1.280G-1, Q&A-24(b) or (c).
(v)For purposes of this Section 6(b), the “After Tax Amount” means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive’s receipt of the Aggregate Payments. For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes.
(vi)The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the “Accounting Firm”), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive. Any determination by the Accounting Firm shall be binding upon the Company and the Executive.
(d)Definitions. For purposes of this Section 6, a “Change in Control” shall mean a “Sale Event” as defined in the Black Diamond Therapeutics, Inc. 2020 Stock Option and Incentive Plan, as may be amended from time to time, but only to the extent such Sale Event is also a “change in control event” within the meaning of Section 409A of the Code and the regulations promulgated thereunder.
7.Section 409A.
(c)Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive’s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a “specified employee” within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive’s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive’s separation from service, or (B) the Executive’s death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.
(d)All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect
8

the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.
(e)To the extent that any payment or benefit described in this Agreement constitutes “non-qualified deferred compensation” under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive’s termination of employment, then such payments or benefits shall be payable only upon the Executive’s “separation from service.” The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-1(h).
(f)The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.
(g)The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.
8.Continuing Obligations.
(e)Restrictive Covenants Agreement. As a condition of employment, the Executive is required to enter into the Employee Confidentiality, Assignment, Nonsolicitation and Noncompetition Agreement, attached hereto as Exhibit A (the “Restrictive Covenants Agreement”). The Executive acknowledges that the benefits of this Agreement, as well as the indemnification agreement to be entered into between the Executive and the Company, to which the Executive was not previously entitled, are fair and reasonable consideration independent from the continuation of employment sufficient to support the Restrictive Covenants Agreement. For purposes of this Agreement, the obligations in this Section 8 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the “Continuing Obligations.”
(f)Third-Party Agreements and Rights. The Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive’s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive’s engagement in any business. The Executive represents to the Company that the Executive’s execution of this Agreement, the Executive’s employment with the Company and the performance of the Executive’s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party. In the Executive’s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.
9

(g)Litigation and Regulatory Cooperation. During and after the Executive’s employment, the Executive shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information. The Executive’s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after the Executive’s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company. The Company shall reimburse the Executive for any reasonable out-of-pocket expenses incurred in connection with the Executive’s performance of obligations pursuant to this Section 8(c).
(h)Relief. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, the Executive agrees that if the Executive breaches, or proposes to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.
(i)Protected Disclosures and Other Protected Action. Nothing in this Agreement shall be interpreted or applied to prohibit the Executive from making any good faith report to any governmental agency or other governmental entity (a “Government Agency”) concerning any act or omission that the Executive reasonably believes constitutes a possible violation of federal or state law or making other disclosures that are protected under the antiretaliation or whistleblower provisions of applicable federal or state law or regulation. In addition, nothing contained in this Agreement limits the Executive’s ability to (i) communicate with any Government Agency or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including the Executive’s ability to provide documents or other information, without notice to the Company, (ii) provide truthful testimony in litigation; or (iii) discuss or disclose information about unlawful acts in the workplace, including harassment, discrimination or other conduct the Executive has reasonable cause to believe is unlawful. In addition, for the avoidance of doubt, pursuant to the federal Defend Trade Secrets Act of 2016, the Executive shall not be held criminally or civilly liable under any federal or state trade secret law or under this Agreement or the Restrictive Covenants Agreement for the disclosure of a trade secret that (a) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (b) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.
9.Consent to Jurisdiction. The parties hereby consent to the exclusive jurisdiction of the state and federal courts of the State of California. Accordingly, with respect to any such court action, the Executive (a) submits to the exclusive personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.
10.Integration. This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, including the Prior Agreement.
10

11.Withholding; Tax Effect. All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law. Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.
12.Assignment. Neither the Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenants Agreement) without the Executive’s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets; provided further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section 5 or pursuant to Section 6 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of the Executive’s and the Company’s respective successors, executors, administrators, heirs and permitted assigns. The Company shall obtain an agreement from any successor to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no succession had taken place, except where such assumption occurs by operation of law.
13.Enforceability. If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.
14.Survival. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive’s employment to the extent necessary to effectuate the terms contained herein.
15.Waiver. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.
16.Notices. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.
17.Amendment. This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.
18.Effect on Other Plans and Agreements. An election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any
11

of the Company’s benefit plans, programs or policies. Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company’s benefit plans, programs or policies except as otherwise provided in Section 8 hereof, and except that the Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise. In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both. Further, Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to both Section 5 and Section 6 of this Agreement.
19.Governing Law. This is a California contract and shall be construed under and be governed in all respects by the laws of the State of California, without giving effect to the conflict of laws principles thereof. With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the First Circuit.
20.Conditions. Notwithstanding anything to the contrary herein, the effectiveness of this Agreement shall be conditioned on (i) the Executive’s satisfactory completion of reference and background checks, if so requested by the Company, and (ii) the Executive’s submission of satisfactory proof of the Executive’s legal authorization to work in the United States.
21.Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.
IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.
BLACK DIAMOND THERAPEUTICS, INC.
By: /s/ Brent Hatzis-Schoch__________________
Its: COO & GC____________________________    
EXECUTIVE
/s/ Sergey Yurasov    
Sergey Yurasov, M.D., Ph.D.
12
 EX-31.1 3 exhibit311_q22022.htm EX-31.1 Document

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO RULE 13a-14(a) OR 15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

I, David M. Epstein, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2022 of Black Diamond Therapeutics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and



5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2022
By:/s/ David M. Epstein
  
David M. Epstein
President, Chief Executive Officer
and Director
(Principal Executive Officer)








 EX-31.2 4 exhibit312_q22022.htm EX-31.2 Document

Exhibit 31.2

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(a) OR 15d-14(a)
OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002

I, Fang Ni, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q for the period ended June 30, 2022 of Black Diamond Therapeutics, Inc.;

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and



5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 9, 2022
By:/s/ Fang Ni
  
Fang Ni
Chief Business and Interim Financial Officer
(Principal Financial Officer)








 EX-32.1 5 exhibit321_q22022.htm EX-32.1 Document

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, David M. Epstein, the Principal Executive Officer, and Fang Ni, the Principal Financial Officer, of Black Diamond Therapeutics, Inc. (the “Company”), hereby certify, that, to their knowledge:

(1)the Quarterly Report on Form 10-Q for the period ended June 30, 2022 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 9, 2022
By:/s/ David M. Epstein
  
David M. Epstein
President, Chief Executive Officer
and Director
(Principal Executive Officer)






Date: August 9, 2022
By:/s/ Fang Ni
  
Fang Ni
Chief Business and Interim Financial Officer
(Principal Financial Officer)








 EX-101.SCH 6 bdtx-20220630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2108104 - Disclosure - INVESTMENTS link:presentationLink link:calculationLink link:definitionLink 2309302 - Disclosure - INVESTMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - INVESTMENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2112105 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 2313303 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 2414405 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 2115106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 2316304 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 2417406 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 2118107 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 2319305 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 2420407 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2421408 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 2422409 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2423410 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2124108 - Disclosure - NET LOSS PER SHARE link:presentationLink link:calculationLink link:definitionLink 2325306 - Disclosure - NET LOSS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 2426411 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2427412 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2128109 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 2329307 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 2430413 - Disclosure - LEASES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2431414 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) link:presentationLink link:calculationLink link:definitionLink 2432415 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2432415 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 2133110 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 2134111 - Disclosure - BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 2435416 - Disclosure - BENEFIT PLANS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 bdtx-20220630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 bdtx-20220630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 bdtx-20220630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Impairment of fair value assets Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale Common stock Increase (Decrease) in Stockholders' Equity [Roll Forward] Adjustment to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Total lease payments Lessee, Operating Lease, Liability, to be Paid Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Additional paid-in capital Additional Paid-in Capital [Member] Open Market Sale Open Market Sale [Member] Open Market Sale Document Fiscal Period Focus Document Fiscal Period Focus Restricted cash Restricted Cash, Noncurrent Property, Plant and Equipment [Abstract] Weighted average common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Gain on lease termination Gain (Loss) on Termination of Lease Investments: Investments, Fair Value Disclosure Property and equipment Property, Plant and Equipment, Gross Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Other income (expense): Other Income and Expenses [Abstract] Common stock; $0.0001 par value; 500,000,000 shares authorized at June 30, 2022 and December 31, 2021; 36,315,737 shares issued and outstanding at June 30, 2022 and 36,234,624 shares issued and outstanding at December 31, 2021 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Financial Instruments [Domain] Financial Instruments [Domain] Area leased (square feet) Lessee, Operating Lease, Area Lessee, Operating Lease, Area Weighted-average grant-date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Statistical Measurement [Domain] Statistical Measurement [Domain] Depreciation expense Depreciation Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Exercise of common stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Vesting of restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Options exercisable, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Short-term lease cost Short-Term Lease, Cost Share-Based Payment Arrangement [Abstract] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Other non-cash items Other Noncash Income (Expense) COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Options vested or expected to vest, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Principal office, lease one Operating Lease, Principal Office, One [Member] Operating Lease, Principal Office, One Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Purchases of equipment included in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Employer contribution, percent of each participant's salary Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay ASC 842 Lessee, Operating Lease, Liability, to be Paid [Abstract] Income Statement Location [Domain] Income Statement Location [Domain] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Equity Component [Domain] Equity Component [Domain] Amendment Flag Amendment Flag Net cash provided by investing activities Net Cash Provided by (Used in) Investing Activities Operating lease cost Operating Lease, Cost Scenario [Axis] Scenario [Axis] Total Assets, Fair Value Disclosure Issuance of common stock related to ESPP Stock Issued During Period, Value, Employee Stock Purchase Plan Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent LEASES Lessee, Operating Leases [Text Block] Proceeds from exercise of common stock options and ESPP Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Plan Name [Axis] Plan Name [Axis] Construction in process Construction in Progress [Member] Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Entity Current Reporting Status Entity Current Reporting Status Other non-current assets Other Assets, Noncurrent Fair Value Debt Securities, Available-for-Sale Weighted Average Remaining Life and Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Noncash rent expense Rent Expense Rent Expense Schedule of Restricted Stock Activity Nonvested Restricted Stock Shares Activity [Table Text Block] 2020 Stock Option Plan 2020 Stock Option Plan [Member] 2020 Stock Option Plan Maximum percent of fair market value of common stock Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Lease Contractual Term [Domain] Lease Contractual Term [Domain] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] 2022 (excluding the six months ended June 30, 2022) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Level 1 Fair Value, Inputs, Level 1 [Member] Lease term (in years) Lessee, Operating Lease, Term of Contract Issuance of common stock related to ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Shares issuable under employee stock purchase plan Employee Stock [Member] Options outstanding, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding, beginning balance (in shares) Outstanding, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Award Type [Axis] Award Type [Axis] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Significant Accounting Policies [Text Block] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current portion of operating lease liability Operating Lease, Liability, Current Principles of consolidation and unaudited interim financial information Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Total Property and Equipment, net Property, Plant and Equipment, Net Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule of Marketable Securities Debt Securities, Available-for-Sale [Table Text Block] Lease Cost Lease, Cost [Abstract] Cash paid for amounts included in the measurement of lease liability Operating Lease, Payments Computer and office equipment Office Equipment [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Stock options Options to purchase common stock Share-Based Payment Arrangement, Option [Member] Other non-current assets Increase (Decrease) in Other Noncurrent Assets Exercise of common stock options Stock Issued During Period, Value, Stock Options Exercised Other (expense) income Other Nonoperating Income (Expense) Common stock, shares authorized (in shares) Common Stock, Shares Authorized Total liabilities Liabilities Increase of authorized shares, percent of common stock outstanding Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Statement of Comprehensive Income [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Total operating expenses Operating Expenses Maximum Maximum [Member] Amortization of premium on investments Investment Income, Net, Amortization of Discount and Premium Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accounts payable Increase (Decrease) in Accounts Payable, Trade Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Total current assets Assets, Current Schedule of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Investments Debt Securities, Available-for-Sale, Current Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Document Type Document Type Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Small Business Entity Small Business Number of shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Measurement Frequency [Domain] Measurement Frequency [Domain] Canceled or forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Shares issued under share-based compensation plan Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Assets: Assets, Fair Value Disclosure [Abstract] Unvested restricted common stock, beginning balance (in dollars per share) Unvested restricted common stock, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value BENEFIT PLANS Compensation and Employee Benefit Plans [Text Block] Entity Shell Company Entity Shell Company Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Options outstanding, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Title of 12(b) Security Title of 12(b) Security Document Period End Date Document Period End Date Payables and Accruals [Abstract] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Stock-based compensation (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Total lease liability Operating Lease, Liability U.S. Government agencies US Government Agencies Debt Securities [Member] Total assets Assets Earnings Per Share [Abstract] Investments, Debt and Equity Securities [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Liabilities and Stockholders' Equity Liabilities and Equity [Abstract] Schedule of Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Accrued expenses and other current liabilities Total accrued expenses and other current liabilities Accrued Liabilities, Current Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Cancelled or forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Accounting Policies [Abstract] Proceeds from stock issuance, net Sale of Stock, Consideration Received on Transaction Payroll and related expenses Employee-related Liabilities, Current Variable lease cost Variable Lease, Cost Accounts payable Accounts Payable, Current Comprehensive loss: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Stockholders' equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Options vested or expected to vest, intrinsic value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value NET LOSS PER SHARE Earnings Per Share [Text Block] Warrants to purchase common stock Warrant [Member] Entity Filer Category Entity Filer Category Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Award Type [Domain] Award Type [Domain] Unrecognized compensation cost, recognition period (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Options exercisable, remaining life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Stock-based compensation expense Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 10) Commitments and Contingencies Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Outstanding, beginning balance (in dollars per share) Outstanding, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2022 and December 31, 2021; no shares issued or outstanding at June 30, 2022 and December 31, 2021 Preferred Stock, Value, Issued Letter of credit outstanding Letters of Credit Outstanding, Amount Unvested restricted stock Restricted Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] General and administrative General and Administrative Expense [Member] Corporate bonds Corporate Bond Securities [Member] Entity Address, City or Town Entity Address, City or Town Change in unrealized loss on investments Unrealized gain (loss) on investments OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax Employer contribution, matching contribution percentage Defined Contribution Plan, Employer Matching Contribution, Percent of Match Number of leases Lessee, Operating Lease, Number Of Contracts Lessee, Operating Lease, Number Of Contracts Leases [Abstract] Operating expenses: Operating Expenses [Abstract] Cover [Abstract] Level 3 Fair Value, Inputs, Level 3 [Member] Principles of consolidation Consolidation, Policy [Policy Text Block] STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Award purchase period (in months) Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forecast Forecast [Member] Commitments and Contingencies Disclosure [Abstract] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Total liabilities and stockholders' equity Liabilities and Equity Trading Symbol Trading Symbol Entity File Number Entity File Number Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Four Lessee, Operating Lease, Liability, Payments, Due after Year Four Research and development Research and Development Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Laboratory equipment Equipment [Member] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Level 2 Fair Value, Inputs, Level 2 [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted stock units Restricted Stock Units (RSUs) [Member] Purchases of investments Payments to Acquire Investments Current Fiscal Year End Date Current Fiscal Year End Date Contracted research services Accrued Contract Research Service Fees, Current Accrued Contract Research Service Fees, Current Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Right-of-use asset derecognized upon early lease termination Right-of-Use Asset, Derecognized, Termination of Lease Right-of-Use Asset, Derecognized, Termination of Lease Net loss per share, diluted (in dollars per share) Net loss per share, diluted (in dollars per share) Earnings Per Share, Diluted Options vested or expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of estimates Use of Estimates, Policy [Policy Text Block] Sale of Stock [Domain] Sale of Stock [Domain] Cash equivalents: Cash and Cash Equivalents, Fair Value Disclosure Other comprehensive income: Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract] 2020 ESPP 2020 Employee Stock Purchase Plan [Member] 2020 Employee Stock Purchase Plan Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Total current liabilities Liabilities, Current 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two INVESTMENTS Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Loss position fair value Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Other Operating Lease Information Lease, Other Information [Abstract] Lease, Other Information [Abstract] Entity Ex Transition Period Entity Ex Transition Period Net loss per share, basic (in dollars per share) Net loss per share, basic (in dollars per share) Earnings Per Share, Basic Performance Restricted Stock Units Performance Restricted Stock Units [Member] Performance Restricted Stock Units 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Employee Stock Purchase Plan and Other Other Award Type [Member] Other Award Type Fair value of units vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Schedule of Future Minimum Lease Payments Lessee, Operating Lease, Liability, Maturity [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Total stockholders' equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Lease Contractual Term [Axis] Lease Contractual Term [Axis] Fair Value Disclosures [Abstract] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Entity Interactive Data Current Entity Interactive Data Current Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Proceeds from sales and maturities of investments Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Changes in current assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract] Money market funds Money Market Funds [Member] Employer contribution amount Defined Contribution Plan, Employer Discretionary Contribution Amount Accumulated deficit Retained Earnings [Member] Unrecognized compensation cost, options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Entity Tax Identification Number Entity Tax Identification Number Total lease cost Lease, Cost Common stock Common Stock [Member] Maximum employee subscription rate Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Schedule of Stock-Based Compensation Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Lease Cost and Other Operating Lease Information Lease, Cost [Table Text Block] Fair value Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three Statement [Table] Statement [Table] Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Lease term, optional extension (in years) Lessee, Operating Lease, Renewal Term Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Non-current operating lease liabilities Increase (Decrease) in Operating Lease Liabilities Increase (Decrease) in Operating Lease Liabilities Document Quarterly Report Document Quarterly Report Furniture and fixtures Furniture and Fixtures [Member] Current assets: Assets, Current [Abstract] Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Statistical Measurement [Axis] Statistical Measurement [Axis] Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Leasehold improvements Leasehold Improvements [Member] Accumulated deficit Retained Earnings (Accumulated Deficit) Interest income Investment Income, Nonoperating Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Equity Components [Axis] Equity Components [Axis] Scenario [Domain] Scenario [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Weighted average grant date fair value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Recurring Fair Value, Recurring [Member] Options exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] City Area Code City Area Code Professional and consulting fees Accrued Professional Fees, Current Statement [Line Items] Statement [Line Items] General and administrative General and Administrative Expense Assets Assets [Abstract] Retirement Benefits [Abstract] Units outstanding (in shares) Unvested restricted common stock, beginning balance (in shares) Unvested restricted common stock, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Total other income (expense), net Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Sale of Stock [Axis] Sale of Stock [Axis] Maximum employee subscription amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Right-of-use assets Operating Lease, Right-of-Use Asset Accumulated other comprehensive income (loss) AOCI Attributable to Parent [Member] Supplemental disclosure of non-cash investing and financing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Principal office, lease two Operating Lease, Principal Office, Two [Member] Operating Lease, Principal Office, Two Options vested or expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report Local Phone Number Local Phone Number Purchases of equipment Payments to Acquire Property, Plant, and Equipment Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Research and development Research and Development Expense [Member] Operating Lease, Office and Laboratory Space, NY Operating Lease, Office and Laboratory Space, NY [Member] Operating Lease, Office and Laboratory Space, NY Recently issued accounting pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Schedule of Computation of Net Loss per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Right-of-use assets obtained in exchange for operating lease obligation Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding NATURE OF BUSINESS AND BASIS OF PRESENTATION Business Description and Basis of Presentation [Text Block] EX-101.PRE 10 bdtx-20220630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.22.2
Cover Page - shares
 6 Months Ended
Jun. 30, 2022
Jul. 28, 2022
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2022  
Document Transition Report false  
Entity File Number 001-38501  
Entity Registrant Name BLACK DIAMOND THERAPEUTICS, INC.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 81-4254660  
Entity Address, Address Line One One Main Street, 14th Floor  
Entity Address, City or Town Cambridge  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02142  
City Area Code (617)  
Local Phone Number 252-0848  
Title of 12(b) Security Common stock, par value $0.0001  
Trading Symbol BDTX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   36,339,466
Amendment Flag false  
Document Fiscal Period Focus Q2  
Document Fiscal Year Focus 2022  
Entity Central Index Key 0001701541  
Current Fiscal Year End Date --12-31  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Current assets:    
Cash and cash equivalents $ 55,877 $ 65,799
Investments 105,013 143,987
Prepaid expenses and other current assets 7,668 5,917
Total current assets 168,558 215,703
Property and equipment, net 2,873 3,035
Restricted cash 1,168 1,223
Right-of-use assets 26,225 27,705
Other non-current assets 10 16
Total assets 198,834 247,682
Current liabilities:    
Accounts payable 2,222 4,107
Accrued expenses and other current liabilities 17,484 19,535
Total current liabilities 19,706 23,642
Non-current operating lease liabilities 26,757 28,140
Total liabilities 46,463 51,782
Commitments and contingencies (Note 10) 0 0
Stockholders' equity:    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June 30, 2022 and December 31, 2021; no shares issued or outstanding at June 30, 2022 and December 31, 2021 0 0
Common stock; $0.0001 par value; 500,000,000 shares authorized at June 30, 2022 and December 31, 2021; 36,315,737 shares issued and outstanding at June 30, 2022 and 36,234,624 shares issued and outstanding at December 31, 2021 5 5
Additional paid-in capital 446,909 440,129
Accumulated other comprehensive loss (2,286) (414)
Accumulated deficit (292,257) (243,820)
Total stockholders' equity 152,371 195,900
Total liabilities and stockholders' equity $ 198,834 $ 247,682
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
Jun. 30, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 10,000,000 10,000,000
Preferred stock, shares outstanding (in shares) 0 0
Preferred stock, shares issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 36,315,737 36,234,624
Common stock, shares outstanding (in shares) 36,315,737 36,234,624
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Operating expenses:        
Research and development $ 16,195 $ 26,719 $ 33,981 $ 49,539
General and administrative 6,978 7,996 14,871 15,889
Total operating expenses 23,173 34,715 48,852 65,428
Loss from operations (23,173) (34,715) (48,852) (65,428)
Other income (expense):        
Interest income 386 948 792 2,100
Other (expense) income (143) (584) (377) (1,324)
Total other income (expense), net 243 364 415 776
Net loss $ (22,930) $ (34,351) $ (48,437) $ (64,652)
Net loss per share, basic (in dollars per share) $ (0.63) $ (0.95) $ (1.33) $ (1.79)
Net loss per share, diluted (in dollars per share) $ (0.63) $ (0.95) $ (1.33) $ (1.79)
Weighted average common shares outstanding, basic (in shares) 36,293,856 36,182,541 36,282,636 36,152,942
Weighted average common shares outstanding, diluted (in shares) 36,293,856 36,182,541 36,282,636 36,152,942
Comprehensive loss:        
Net loss $ (22,930) $ (34,351) $ (48,437) $ (64,652)
Other comprehensive income:        
Change in unrealized loss on investments (511) (124) (1,872) (403)
Comprehensive loss $ (23,441) $ (34,475) $ (50,309) $ (65,055)
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Cash flows from operating activities:    
Net loss $ (48,437) $ (64,652)
Adjustment to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 6,627 7,652
Depreciation expense 253 39
Amortization of premium on investments 365 1,326
Noncash rent expense 1,371 748
Other non-cash items 0 (14)
Loss on disposal of property and equipment 3 0
Changes in current assets and liabilities:    
Prepaid expenses and other current assets (1,751) (2,956)
Other non-current assets 6 8
Accounts payable (1,885) 1,635
Accrued expenses and other current liabilities (1,836) 7,355
Non-current operating lease liabilities (1,383) (761)
Net cash used in operating activities (46,667) (49,620)
Cash flows from investing activities:    
Purchases of equipment (200) (888)
Proceeds from sales and maturities of investments 57,241 95,138
Purchases of investments (20,504) (42,576)
Net cash provided by investing activities 36,537 51,674
Cash flows from financing activities:    
Proceeds from exercise of common stock options and ESPP 153 665
Net cash provided by financing activities 153 665
Net (decrease) increase in cash and cash equivalents (9,977) 2,719
Cash, cash equivalents and restricted cash, beginning of period 67,022 35,828
Cash, cash equivalents and restricted cash, end of period 57,045 38,547
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents    
Cash and cash equivalents 55,877 37,324
Restricted cash 1,168 1,223
Cash, cash equivalents and restricted cash, end of period 57,045 38,547
Supplemental disclosure of non-cash investing and financing activities:    
Purchases of equipment included in accounts payable and accrued expenses 0 1,199
Right-of-use assets obtained in exchange for operating lease obligation 109 5,717
Right-of-use asset derecognized upon early lease termination $ 0 $ 476
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2020   36,078,383      
Beginning balance at Dec. 31, 2020 $ 307,758 $ 5 $ 425,363 $ 614 $ (118,224)
Common stock          
Exercise of common stock options (in shares)   62,607      
Exercise of common stock options 481   481    
Vesting of restricted stock units (in shares)   4,998      
Stock-based compensation (in shares)   1,224      
Stock-based compensation 3,094   3,094    
Unrealized gain (loss) on investments (279)     (279)  
Net loss (30,301)       (30,301)
Ending balance (in shares) at Mar. 31, 2021   36,147,212      
Ending balance at Mar. 31, 2021 280,753 $ 5 428,938 335 (148,525)
Beginning balance (in shares) at Dec. 31, 2020   36,078,383      
Beginning balance at Dec. 31, 2020 307,758 $ 5 425,363 614 (118,224)
Common stock          
Unrealized gain (loss) on investments (403)        
Net loss (64,652)        
Ending balance (in shares) at Jun. 30, 2021   36,205,826      
Ending balance at Jun. 30, 2021 251,020 $ 5 433,680 211 (182,876)
Beginning balance (in shares) at Mar. 31, 2021   36,147,212      
Beginning balance at Mar. 31, 2021 280,753 $ 5 428,938 335 (148,525)
Common stock          
Exercise of common stock options (in shares)   48,014      
Exercise of common stock options 184   184    
Vesting of restricted stock units (in shares)   8,331      
Stock-based compensation (in shares)   2,269      
Stock-based compensation 4,558   4,558    
Unrealized gain (loss) on investments (124)     (124)  
Net loss (34,351)       (34,351)
Ending balance (in shares) at Jun. 30, 2021   36,205,826      
Ending balance at Jun. 30, 2021 $ 251,020 $ 5 433,680 211 (182,876)
Beginning balance (in shares) at Dec. 31, 2021 36,234,624 36,234,624      
Beginning balance at Dec. 31, 2021 $ 195,900 $ 5 440,129 (414) (243,820)
Common stock          
Exercise of common stock options (in shares)   3,565      
Exercise of common stock options 11   11    
Vesting of restricted stock units (in shares)   5,000      
Issuance of common stock related to ESPP (in shares)   31,341      
Issuance of common stock related to ESPP 142   142    
Stock-based compensation (in shares)   13,038      
Stock-based compensation 3,375   3,375    
Unrealized gain (loss) on investments (1,361)     (1,361)  
Net loss (25,507)       (25,507)
Ending balance (in shares) at Mar. 31, 2022   36,287,568      
Ending balance at Mar. 31, 2022 $ 172,560 $ 5 443,657 (1,775) (269,327)
Beginning balance (in shares) at Dec. 31, 2021 36,234,624 36,234,624      
Beginning balance at Dec. 31, 2021 $ 195,900 $ 5 440,129 (414) (243,820)
Common stock          
Exercise of common stock options (in shares) 3,565        
Unrealized gain (loss) on investments $ (1,872)        
Net loss $ (48,437)        
Ending balance (in shares) at Jun. 30, 2022 36,315,737        
Ending balance at Jun. 30, 2022 $ 152,371 $ 5 446,909 (2,286) (292,257)
Beginning balance (in shares) at Mar. 31, 2022   36,287,568      
Beginning balance at Mar. 31, 2022 172,560 $ 5 443,657 (1,775) (269,327)
Common stock          
Vesting of restricted stock units (in shares)   3,333      
Stock-based compensation (in shares)   24,836      
Stock-based compensation 3,252   3,252    
Unrealized gain (loss) on investments (511)     (511)  
Net loss $ (22,930)       (22,930)
Ending balance (in shares) at Jun. 30, 2022 36,315,737        
Ending balance at Jun. 30, 2022 $ 152,371 $ 5 $ 446,909 $ (2,286) $ (292,257)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.22.2
NATURE OF BUSINESS AND BASIS OF PRESENTATION
 6 Months Ended
Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF BUSINESS AND BASIS OF PRESENTATION NATURE OF BUSINESS AND BASIS OF PRESENTATION
Black Diamond Therapeutics, Inc. (the “Company”) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of its mutation, allostery, and pharmacology computational and drug discovery engine.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
On February 1, 2021, the Company filed a shelf registration statement on Form S-3 ASR (the “Shelf”), with the Securities and Exchange Commission (the “SEC”), which covers the offering, issuance and sale of the Company’s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. The Company simultaneously entered into an Open Market Sale AgreementSM with Jefferies LLC, as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies as its sales agent (the “ATM Program”). The Shelf became automatically effective upon filing on February 1, 2021. As of June 30, 2022, no sales have been made pursuant to the ATM Program.
The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred and common stock. The Company expects to continue to generate operating losses for the foreseeable future.
As of August 9, 2022, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.
The Company may seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.
The ongoing COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions, and other public health safety measures.
The Company has been closely monitoring the impact of the ongoing COVID-19 pandemic on all aspects of the Company’s business, including how it has impacted and may continue to impact the Company’s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment’s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company’s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company’s third party service providers have also experienced shutdowns or other business disruptions.
The extent to which COVID-19 ultimately impacts the Company’s business, results of operations or financial condition will depend on future developments, which, despite progress in vaccination efforts, remain highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, new strains of the virus, including any future variants that may emerge, which may impact rates of infection and vaccination efforts, developments or perceptions regarding the safety of vaccines, new information that may emerge concerning the severity of COVID-19, and any additional preventative and protective actions taken to contain the pandemic or treat its impact, among others. The Company does not yet know the full extent of potential delays or impacts on the Company’s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions but if the Company or any of the third parties with whom it engages were to experience prolonged business shutdowns or other disruptions, the Company’s ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on the Company’s business, results of operations and financial condition. The estimates of the impact on the Company’s business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.22.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.
Principles of consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.
Unaudited interim financial information
The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
Use of estimates
The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.
Recently issued accounting pronouncements
The Company believes that no recently issued accounting standards will have a material impact on its condensed consolidated financial statements, or apply to its operations.
XML 19 R9.htm IDEA: XBRL DOCUMENT v3.22.2
FAIR VALUE MEASUREMENTS
 6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTSThe following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

Fair value measurements at June 30, 2022 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$53,761 $— $— $53,761 
Investments:
Commercial paper— 14,542 — 14,542 
Corporate bonds— 51,487 — 51,487 
U.S. Government agencies— 38,984 — 38,984 
Total$53,761 $105,013 $— $158,774 

Fair value measurements at December 31, 2021 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$63,730 $— $— $63,730 
Investments:
Corporate bonds— 104,066 — 104,066 
U.S. Government agencies— 39,921 — 39,921 
Total$63,730 $143,987 $— $207,717 
When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument.
There were no transfers in or out of Level 3 categories in the periods presented.
XML 20 R10.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENTS
 6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
INVESTMENTS INVESTMENTS
As of June 30, 2022, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$14,547 $— $(5)$14,542 
Corporate bonds52,620 — (1,133)51,487 
U.S. Government agencies40,132 — (1,148)38,984 
Total$107,299 $— $(2,286)$105,013 
As of December 31, 2021, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Corporate bonds$104,261 $47 $(242)$104,066 
U.S. Government agencies40,140 — (219)39,921 
Total$144,401 $47 $(461)$143,987 
As of June 30, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $47,880 that had maturities of one to three years.
As of December 31, 2021, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies and corporate bonds with a fair value of $86,187 that had maturities of one to three years.
As of June 30, 2022, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $47,880, that had maturities of one to three years. As of December 31, 2021, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies and corporate bonds, with a fair value of $86,187, that had maturities of one to three years.
As of June 30, 2022, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were temporary. In determining whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. There have been no impairments of the Company’s assets measured and carried at fair value during the six months ended June 30, 2022 and the year ended December 31, 2021.
XML 21 R11.htm IDEA: XBRL DOCUMENT v3.22.2
PROPERTY AND EQUIPMENT
 6 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT
Property and equipment, net consisted of the following:

June 30,
2022

December 31,
2021
Laboratory equipment$807 $682 
Furniture and fixtures17 17 
Computer and office equipment120 120 
Leasehold improvements2,512 2,437 
Construction in process— 148 
Property and equipment3,456 3,404 
Less: accumulated depreciation(583)(369)
Total Property and Equipment, net$2,873 $3,035 

Depreciation expense for the six months ended June 30, 2022 and 2021 was $253 and $39, respectively.
XML 22 R12.htm IDEA: XBRL DOCUMENT v3.22.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
 6 Months Ended
Jun. 30, 2022
Payables and Accruals [Abstract]  
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following:

June 30,
2022

December 31,
2021
Contracted research services$11,072 $12,192 
Payroll and related expenses3,352 5,088 
Professional and consulting fees971 1,935 
Current portion of operating lease liability2,089 320 
Total accrued expenses and other current liabilities$17,484 $19,535 
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.22.2
STOCK-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION STOCK-BASED COMPENSATION
2020 Stock Option and Incentive Plan
The 2020 Stock Option and Incentive Plan (the “2020 Plan”) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company’s initial public offering (“IPO”) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, 2022, 1,449,384 shares of common stock, representing 4% of the Company’s outstanding shares of common stock as of December 31, 2021, were added to the 2020 Plan.
2020 Employee Stock Purchase Plan
The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2022.
Stock-based compensation expense
The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2022202120222021
Stock options$3,000 $4,216 $6,193 $7,010 
Restricted stock units189 290 310 560 
Employee Stock Purchase Plan and Other63 52 124 82 

$3,252 $4,558 $6,627 $7,652 
For the six months ended June 30, 2022, the Company issued 37,874 shares of common stock out of its 2020 Plan under its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.
The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2022

202120222021
Research and development$1,526 

$2,234 $3,054 $3,854 
General and administrative1,726 

2,324 3,573 3,798 

$3,252 

$4,558 $6,627 $7,652 
Options
The following table summarizes the stock option activity under the Company’s equity awards plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life
(in Years)

Intrinsic
Value
(in thousands)
Outstanding December 31, 20214,903,839 $17.38 7.6$847 
Granted1,816,650 $3.33 
Exercised(3,565)$3.20 
Cancelled or forfeited(691,330)$16.50 
Outstanding June 30, 20226,025,594 $13.25 8.0$289 
Options vested or expected to vest at June 30, 20226,025,594 $13.25 8.0$289 
Options exercisable at June 30, 20222,478,157 $16.05 6.9$45 
For the six months ended June 30, 2022, total unrecognized compensation cost related to the unvested stock-options was $23,832, which is expected to be recognized over a weighted average period of 2.2 years.
Restricted stock units
The fair values of restricted stock units are based on the market value of the Company’s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2022:

Number of
shares
Weighted
average
grant date
fair value
Unvested restricted common stock as of December 31, 202130,667 $29.53 
Granted185,795 $2.32 
Vested(8,333)$29.24 
Unvested restricted common stock as of June 30, 2022208,129 $5.25 
The total fair value of time-based restricted stock units vested during the six months ended June 30, 2022 was $244.
For the six months ended June 30, 2022, total unrecognized compensation cost related to the time-based unvested restricted stock units was $757, which is expected to be recognized over a weighted average period of 1.3 years.
For the three months ended June 30, 2022, the Company granted to its employees 55,125 performance restricted stock units related to the achievement of certain clinical development and/or financing milestones. As of June 30, 2022, the Company had 267,125 performance restricted stock units outstanding.
Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management’s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.
As of June 30, 2022, for performance-based restricted stock units that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore no expense has been recognized related to these awards in the six months ended June 30, 2022.
Employee stock purchase plan
The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee’s eligible compensation for each payroll period, up to $25 each calendar year.
During the six months ended June 30, 2022 and 2021, there were 31,341 and no shares, respectively, issued under the 2020 ESPP.
XML 24 R14.htm IDEA: XBRL DOCUMENT v3.22.2
NET LOSS PER SHARE
 6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
NET LOSS PER SHARE NET LOSS PER SHARE
Net loss per share
The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):

Three Months Ended
June 30,		Six Months Ended
June 30,

2022

202120222021
Net loss$(22,930)

$(34,351)$(48,437)$(64,652)
Weighted average common shares outstanding, basic and diluted36,293,856 

36,182,541 36,282,636 36,152,942 
Net loss per share, basic and diluted$(0.63)

$(0.95)$(1.33)$(1.79)

The Company’s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
Six Months Ended
June 30,

20222021
Options to purchase common stock6,025,594 5,209,744 
Unvested restricted stock208,129 51,007 
Shares issuable under employee stock purchase plan27,572 2,940 
Warrants to purchase common stock10,757 10,757 

6,272,052 5,274,448 
XML 25 R15.htm IDEA: XBRL DOCUMENT v3.22.2
LEASES
 6 Months Ended
Jun. 30, 2022
Leases [Abstract]  
LEASES LEASES
The Company has historically entered into lease arrangements for its facilities. As of June 30, 2022, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options.
Operating leases
In July 2020, the Company entered into a seven-year agreement with an option to extend for five additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease.
The Company previously leased an office space in Cambridge, MA under a lease that commenced in February 2019 for approximately 2,357 square feet of office space, which was set to expire on April 30, 2022, subject to an option to extend the lease for three additional years. Effective June 15, 2021, the lease was terminated, and the remaining right-of-use asset and lease liability were derecognized. A gain of $5 was recognized for the termination of the lease.
In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for five additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2022 and 2021:
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Lease Cost
Operating lease cost$1,057 $613 $2,116 $1,075 
Short-term lease cost21 288 40 575 
Variable lease cost219 43 476 76 
Total lease cost$1,297 $944 $2,632 $1,726 
Other Operating Lease InformationJune 30, 2022June 30, 2021
Cash paid for amounts included in the measurement of lease liability$1,290 $732 
Weighted-average remaining lease term8.37.1
Weighted-average discount rate5.3 %5.3 %
The variable lease costs for the three and six months ended June 30, 2022 and 2021 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.
Future minimum lease payments under the Company’s operating leases as of June 30, 2022 were as follows:
As of June 30, 2022
2022 (excluding the six months ended June 30, 2022)
$1,460 
20234,244 
20244,359 
20254,477 
20264,599 
Thereafter16,973 
Total lease payments36,112 
Less: interest(7,266)
Total lease liability$28,846 
XML 26 R16.htm IDEA: XBRL DOCUMENT v3.22.2
COMMITMENTS AND CONTINGENCIES
 6 Months Ended
Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
The Company enters into contracts in the normal course of business with contract research organizations ("CROs"), contract manufacturing organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.
License agreements
The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of June 30, 2022, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.
Indemnification agreements
In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2022 or December 31, 2021.
Legal proceedings
The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.
XML 27 R17.htm IDEA: XBRL DOCUMENT v3.22.2
BENEFIT PLANS
 6 Months Ended
Jun. 30, 2022
Retirement Benefits [Abstract]  
BENEFIT PLANS BENEFIT PLANSThe Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the “401(k) Plan”). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant’s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). All matching contributions are fully vested when made. During the three and six months ended June 30, 2022 and 2021, the Company contributed $199, $757, $220 and $565, respectively, to the 401(k) Plan.
XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 6 Months Ended
Jun. 30, 2022
Accounting Policies [Abstract]  
Principles of consolidation and unaudited interim financial information
Black Diamond Therapeutics, Inc. (the “Company”) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of its mutation, allostery, and pharmacology computational and drug discovery engine.
The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.
Principles of consolidation
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.
Unaudited interim financial information
The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.
Principles of consolidation Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions.
Use of estimates Use of estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions.
Recently issued accounting pronouncements
Recently issued accounting pronouncements
The Company believes that no recently issued accounting standards will have a material impact on its condensed consolidated financial statements, or apply to its operations.
XML 29 R19.htm IDEA: XBRL DOCUMENT v3.22.2
FAIR VALUE MEASUREMENTS (Tables)
 6 Months Ended
Jun. 30, 2022
Fair Value Disclosures [Abstract]  
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values:

Fair value measurements at June 30, 2022 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$53,761 $— $— $53,761 
Investments:
Commercial paper— 14,542 — 14,542 
Corporate bonds— 51,487 — 51,487 
U.S. Government agencies— 38,984 — 38,984 
Total$53,761 $105,013 $— $158,774 

Fair value measurements at December 31, 2021 using:

Level 1

Level 2Level 3Total
Assets:





Cash equivalents:
Money market funds$63,730 $— $— $63,730 
Investments:
Corporate bonds— 104,066 — 104,066 
U.S. Government agencies— 39,921 — 39,921 
Total$63,730 $143,987 $— $207,717 
XML 30 R20.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENTS (Tables)
 6 Months Ended
Jun. 30, 2022
Investments, Debt and Equity Securities [Abstract]  
Schedule of Marketable Securities
As of June 30, 2022, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Commercial paper$14,547 $— $(5)$14,542 
Corporate bonds52,620 — (1,133)51,487 
U.S. Government agencies40,132 — (1,148)38,984 
Total$107,299 $— $(2,286)$105,013 
As of December 31, 2021, investments were comprised of the following:
Amortized Cost

Unrealized GainsUnrealized LossesFair Value
Corporate bonds$104,261 $47 $(242)$104,066 
U.S. Government agencies40,140 — (219)39,921 
Total$144,401 $47 $(461)$143,987 
XML 31 R21.htm IDEA: XBRL DOCUMENT v3.22.2
PROPERTY AND EQUIPMENT (Tables)
 6 Months Ended
Jun. 30, 2022
Property, Plant and Equipment [Abstract]  
Schedule of Property, Plant and Equipment Property and equipment, net consisted of the following:

June 30,
2022

December 31,
2021
Laboratory equipment$807 $682 
Furniture and fixtures17 17 
Computer and office equipment120 120 
Leasehold improvements2,512 2,437 
Construction in process— 148 
Property and equipment3,456 3,404 
Less: accumulated depreciation(583)(369)
Total Property and Equipment, net$2,873 $3,035 
XML 32 R22.htm IDEA: XBRL DOCUMENT v3.22.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)
 6 Months Ended
Jun. 30, 2022
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses Accrued expenses and other current liabilities consisted of the following:

June 30,
2022

December 31,
2021
Contracted research services$11,072 $12,192 
Payroll and related expenses3,352 5,088 
Professional and consulting fees971 1,935 
Current portion of operating lease liability2,089 320 
Total accrued expenses and other current liabilities$17,484 $19,535 
XML 33 R23.htm IDEA: XBRL DOCUMENT v3.22.2
STOCK-BASED COMPENSATION (Tables)
 6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2022202120222021
Stock options$3,000 $4,216 $6,193 $7,010 
Restricted stock units189 290 310 560 
Employee Stock Purchase Plan and Other63 52 124 82 

$3,252 $4,558 $6,627 $7,652 
The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:
Three Months Ended
June 30,		Six Months Ended
June 30,

2022

202120222021
Research and development$1,526 

$2,234 $3,054 $3,854 
General and administrative1,726 

2,324 3,573 3,798 

$3,252 

$4,558 $6,627 $7,652 
Schedule of Stock Option Activity The following table summarizes the stock option activity under the Company’s equity awards plans:

Options

Weighted
Average
Exercise
Price

Weighted
Average
Remaining
Life
(in Years)

Intrinsic
Value
(in thousands)
Outstanding December 31, 20214,903,839 $17.38 7.6$847 
Granted1,816,650 $3.33 
Exercised(3,565)$3.20 
Cancelled or forfeited(691,330)$16.50 
Outstanding June 30, 20226,025,594 $13.25 8.0$289 
Options vested or expected to vest at June 30, 20226,025,594 $13.25 8.0$289 
Options exercisable at June 30, 20222,478,157 $16.05 6.9$45 
Schedule of Restricted Stock Activity The following table summarizes time-based restricted stock activity since January 1, 2022:

Number of
shares
Weighted
average
grant date
fair value
Unvested restricted common stock as of December 31, 202130,667 $29.53 
Granted185,795 $2.32 
Vested(8,333)$29.24 
Unvested restricted common stock as of June 30, 2022208,129 $5.25 
XML 34 R24.htm IDEA: XBRL DOCUMENT v3.22.2
NET LOSS PER SHARE (Tables)
 6 Months Ended
Jun. 30, 2022
Earnings Per Share [Abstract]  
Schedule of Computation of Net Loss per Share The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):

Three Months Ended
June 30,		Six Months Ended
June 30,

2022

202120222021
Net loss$(22,930)

$(34,351)$(48,437)$(64,652)
Weighted average common shares outstanding, basic and diluted36,293,856 

36,182,541 36,282,636 36,152,942 
Net loss per share, basic and diluted$(0.63)

$(0.95)$(1.33)$(1.79)
Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:
Six Months Ended
June 30,

20222021
Options to purchase common stock6,025,594 5,209,744 
Unvested restricted stock208,129 51,007 
Shares issuable under employee stock purchase plan27,572 2,940 
Warrants to purchase common stock10,757 10,757 

6,272,052 5,274,448 
XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.2
LEASES (Tables)
 6 Months Ended
Jun. 30, 2022
Leases [Abstract]  
Summary of Lease Cost and Other Operating Lease Information
The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2022 and 2021:
Three Months Ended June 30,Six Months Ended June 30,
2022202120222021
Lease Cost
Operating lease cost$1,057 $613 $2,116 $1,075 
Short-term lease cost21 288 40 575 
Variable lease cost219 43 476 76 
Total lease cost$1,297 $944 $2,632 $1,726 
Other Operating Lease InformationJune 30, 2022June 30, 2021
Cash paid for amounts included in the measurement of lease liability$1,290 $732 
Weighted-average remaining lease term8.37.1
Weighted-average discount rate5.3 %5.3 %
Schedule of Future Minimum Lease Payments Future minimum lease payments under the Company’s operating leases as of June 30, 2022 were as follows:
As of June 30, 2022
2022 (excluding the six months ended June 30, 2022)
$1,460 
20234,244 
20244,359 
20254,477 
20264,599 
Thereafter16,973 
Total lease payments36,112 
Less: interest(7,266)
Total lease liability$28,846 
XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.2
NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)
$ in Millions
 3 Months Ended
Sep. 30, 2022
USD ($)
Open Market Sale | Maximum | Forecast  
Subsidiary, Sale of Stock [Line Items]  
Proceeds from stock issuance, net $ 150
XML 37 R27.htm IDEA: XBRL DOCUMENT v3.22.2
FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - Recurring - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Assets:    
Total $ 158,774 $ 207,717
Money market funds    
Assets:    
Cash equivalents: 53,761 63,730
Commercial paper    
Assets:    
Investments: 14,542  
Corporate bonds    
Assets:    
Investments: 51,487 104,066
U.S. Government agencies    
Assets:    
Investments: 38,984 39,921
Level 1    
Assets:    
Total 53,761 63,730
Level 1 | Money market funds    
Assets:    
Cash equivalents: 53,761 63,730
Level 1 | Commercial paper    
Assets:    
Investments: 0  
Level 1 | Corporate bonds    
Assets:    
Investments: 0 0
Level 1 | U.S. Government agencies    
Assets:    
Investments: 0 0
Level 2    
Assets:    
Total 105,013 143,987
Level 2 | Money market funds    
Assets:    
Cash equivalents: 0 0
Level 2 | Commercial paper    
Assets:    
Investments: 14,542  
Level 2 | Corporate bonds    
Assets:    
Investments: 51,487 104,066
Level 2 | U.S. Government agencies    
Assets:    
Investments: 38,984 39,921
Level 3    
Assets:    
Total 0 0
Level 3 | Money market funds    
Assets:    
Cash equivalents: 0 0
Level 3 | Commercial paper    
Assets:    
Investments: 0  
Level 3 | Corporate bonds    
Assets:    
Investments: 0 0
Level 3 | U.S. Government agencies    
Assets:    
Investments: $ 0 $ 0
XML 38 R28.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENTS - Schedule of Marketable Securities (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost $ 107,299 $ 144,401
Unrealized Gains 0 47
Unrealized Losses (2,286) (461)
Fair Value 105,013 143,987
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 14,547  
Unrealized Gains 0  
Unrealized Losses (5)  
Fair Value 14,542  
Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 52,620 104,261
Unrealized Gains 0 47
Unrealized Losses (1,133) (242)
Fair Value 51,487 104,066
U.S. Government agencies    
Debt Securities, Available-for-sale [Line Items]    
Amortized Cost 40,132 40,140
Unrealized Gains 0 0
Unrealized Losses (1,148) (219)
Fair Value $ 38,984 $ 39,921
XML 39 R29.htm IDEA: XBRL DOCUMENT v3.22.2
INVESTMENTS - Additional Information (Details) - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]    
Fair value $ 47,880,000 $ 86,187,000
Loss position fair value 47,880,000 86,187,000
Impairment of fair value assets $ 0 $ 0
XML 40 R30.htm IDEA: XBRL DOCUMENT v3.22.2
PROPERTY AND EQUIPMENT (Details) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Dec. 31, 2021
Property, Plant and Equipment [Line Items]      
Property and equipment $ 3,456   $ 3,404
Less: accumulated depreciation (583)   (369)
Total Property and Equipment, net 2,873   3,035
Depreciation expense 253 $ 39  
Laboratory equipment      
Property, Plant and Equipment [Line Items]      
Property and equipment 807   682
Furniture and fixtures      
Property, Plant and Equipment [Line Items]      
Property and equipment 17   17
Computer and office equipment      
Property, Plant and Equipment [Line Items]      
Property and equipment 120   120
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property and equipment 2,512   2,437
Construction in process      
Property, Plant and Equipment [Line Items]      
Property and equipment $ 0   $ 148
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.22.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)
$ in Thousands
Jun. 30, 2022
Dec. 31, 2021
Payables and Accruals [Abstract]    
Contracted research services $ 11,072 $ 12,192
Payroll and related expenses 3,352 5,088
Professional and consulting fees $ 971 $ 1,935
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Total accrued expenses and other current liabilities Total accrued expenses and other current liabilities
Current portion of operating lease liability $ 2,089 $ 320
Total accrued expenses and other current liabilities $ 17,484 $ 19,535
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.22.2
STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jan. 01, 2022
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Jan. 14, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Unrecognized compensation cost, options   $ 23,832   $ 23,832    
Stock-based compensation expense   3,252 $ 4,558 $ 6,627 $ 7,652  
2020 Stock Option Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Increase of authorized shares, percent of common stock outstanding 4.00%         4.00%
Number of additional shares authorized (in shares) 1,449,384          
2020 ESPP            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Increase of authorized shares, percent of common stock outstanding           1.00%
Number of additional shares authorized (in shares) 326,364          
Stock options            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Unrecognized compensation cost, recognition period (in years)       2 years 2 months 12 days    
Stock-based compensation expense   3,000 4,216 $ 6,193 7,010  
Stock options | 2020 Stock Option Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares issued under share-based compensation plan       37,874    
Restricted stock units            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Unrecognized compensation cost, recognition period (in years)       1 year 3 months 18 days    
Fair value of units vested       $ 244    
Unrecognized compensation cost   757   757    
Stock-based compensation expense   $ 189 $ 290 $ 310 $ 560  
Shares issuable under employee stock purchase plan | 2020 ESPP            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Shares issued under share-based compensation plan       31,341 0  
Award purchase period (in months)       6 months    
Maximum percent of fair market value of common stock       85.00%    
Maximum employee subscription rate   10.00%   10.00%    
Maximum employee subscription amount       $ 25    
Performance Restricted Stock Units            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Granted (in shares)       55,125    
Units outstanding (in shares)   267,125   267,125    
Stock-based compensation expense       $ 0    
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.22.2
STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense $ 3,252 $ 4,558 $ 6,627 $ 7,652
Research and development        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense 1,526 2,234 3,054 3,854
General and administrative        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense 1,726 2,324 3,573 3,798
Stock options        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense 3,000 4,216 6,193 7,010
Restricted stock units        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense 189 290 310 560
Employee Stock Purchase Plan and Other        
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]        
Stock-based compensation expense $ 63 $ 52 $ 124 $ 82
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.22.2
STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2022
Dec. 31, 2021
Options    
Outstanding, beginning balance (in shares) 4,903,839  
Granted (in shares) 1,816,650  
Exercised (in shares) (3,565)  
Canceled or forfeited (in shares) (691,330)  
Outstanding, ending balance (in shares) 6,025,594 4,903,839
Options vested or expected to vest (in shares) 6,025,594  
Options exercisable (in shares) 2,478,157  
Weighted Average Exercise Price    
Outstanding, beginning balance (in dollars per share) $ 17.38  
Granted (in dollars per share) 3.33  
Exercised (in dollars per share) 3.20  
Cancelled or forfeited (in dollars per share) 16.50  
Outstanding, ending balance (in dollars per share) 13.25 $ 17.38
Options vested or expected to vest (in dollars per share) 13.25  
Options exercisable (in dollars per share) $ 16.05  
Weighted Average Remaining Life and Intrinsic Value    
Options outstanding, remaining life (in years) 8 years 7 years 7 months 6 days
Options vested or expected to vest, remaining life (in years) 8 years  
Options exercisable, remaining life (in years) 6 years 10 months 24 days  
Options outstanding, intrinsic value $ 289 $ 847
Options vested or expected to vest, intrinsic value 289  
Options exercisable, intrinsic value $ 45  
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.22.2
STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) - Unvested restricted stock
 6 Months Ended
Jun. 30, 2022
$ / shares
shares
Number of shares  
Unvested restricted common stock, beginning balance (in shares) | shares 30,667
Granted (in shares) | shares 185,795
Vested (in shares) | shares (8,333)
Unvested restricted common stock, ending balance (in shares) | shares 208,129
Weighted average grant date fair value  
Unvested restricted common stock, beginning balance (in dollars per share) | $ / shares $ 29.53
Weighted-average grant-date fair value (in dollars per share) | $ / shares 2.32
Vested (in dollars per share) | $ / shares 29.24
Unvested restricted common stock, ending balance (in dollars per share) | $ / shares $ 5.25
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.22.2
NET LOSS PER SHARE - Computation of Net Loss per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Mar. 31, 2022
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2022
Jun. 30, 2021
Earnings Per Share [Abstract]            
Net loss $ (22,930) $ (25,507) $ (34,351) $ (30,301) $ (48,437) $ (64,652)
Weighted average common shares outstanding, basic (in shares) 36,293,856   36,182,541   36,282,636 36,152,942
Weighted average common shares outstanding, diluted (in shares) 36,293,856   36,182,541   36,282,636 36,152,942
Net loss per share, basic (in dollars per share) $ (0.63)   $ (0.95)   $ (1.33) $ (1.79)
Net loss per share, diluted (in dollars per share) $ (0.63)   $ (0.95)   $ (1.33) $ (1.79)
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2
NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) - shares
 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 6,272,052 5,274,448
Options to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 6,025,594 5,209,744
Unvested restricted stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 208,129 51,007
Shares issuable under employee stock purchase plan    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 27,572 2,940
Warrants to purchase common stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) 10,757 10,757
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.22.2
LEASES - Narrative (Details)
$ in Thousands
 6 Months Ended
Jun. 15, 2021
USD ($)
Jun. 30, 2022
contract
Dec. 31, 2020
ft²
Jul. 31, 2020
USD ($)
ft²
Feb. 28, 2019
ft²
Lessee, Lease, Description [Line Items]          
Number of leases | contract   2      
Gain on lease termination | $ $ 5        
Principal office, lease two          
Lessee, Lease, Description [Line Items]          
Lease term (in years)       7 years  
Lease term, optional extension (in years)       5 years  
Area leased (square feet)       25,578  
Letter of credit outstanding | $       $ 1,168  
Principal office, lease one          
Lessee, Lease, Description [Line Items]          
Lease term, optional extension (in years)         3 years
Area leased (square feet)         2,357
Operating Lease, Office and Laboratory Space, NY          
Lessee, Lease, Description [Line Items]          
Lease term (in years)     11 years    
Lease term, optional extension (in years)     5 years    
Area leased (square feet)     18,120    
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.22.2
LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Lease Cost        
Operating lease cost $ 1,057 $ 613 $ 2,116 $ 1,075
Short-term lease cost 21 288 40 575
Variable lease cost 219 43 476 76
Total lease cost $ 1,297 $ 944 2,632 1,726
Other Operating Lease Information        
Cash paid for amounts included in the measurement of lease liability     $ 1,290 $ 732
Weighted-average remaining lease term (in years) 8 years 3 months 18 days 7 years 1 month 6 days 8 years 3 months 18 days 7 years 1 month 6 days
Weighted-average discount rate 5.30% 5.30% 5.30% 5.30%
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.22.2
LEASES - Schedule of Future Minimum Lease Payments (Details)
$ in Thousands
Jun. 30, 2022
USD ($)
ASC 842  
2022 (excluding the six months ended June 30, 2022) $ 1,460
2023 4,244
2024 4,359
2025 4,477
2026 4,599
Thereafter 16,973
Total lease payments 36,112
Less: interest (7,266)
Total lease liability $ 28,846
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.22.2
BENEFIT PLANS (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Retirement Benefits [Abstract]        
Employer contribution, matching contribution percentage     100.00%  
Employer contribution, percent of each participant's salary     6.00%  
Employer contribution amount $ 199 $ 220 $ 757 $ 565
XML 52 bdtx-20220630_htm.xml IDEA: XBRL DOCUMENT 0001701541 2022-01-01 2022-06-30 0001701541 2022-07-28 0001701541 2022-06-30 0001701541 2021-12-31 0001701541 2022-04-01 2022-06-30 0001701541 2021-04-01 2021-06-30 0001701541 2021-01-01 2021-06-30 0001701541 2020-12-31 0001701541 2021-06-30 0001701541 us-gaap:CommonStockMember 2020-12-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001701541 us-gaap:RetainedEarningsMember 2020-12-31 0001701541 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001701541 2021-01-01 2021-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001701541 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001701541 us-gaap:CommonStockMember 2021-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001701541 us-gaap:RetainedEarningsMember 2021-03-31 0001701541 2021-03-31 0001701541 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001701541 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001701541 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001701541 us-gaap:CommonStockMember 2021-06-30 0001701541 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001701541 us-gaap:RetainedEarningsMember 2021-06-30 0001701541 us-gaap:CommonStockMember 2021-12-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001701541 us-gaap:RetainedEarningsMember 2021-12-31 0001701541 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001701541 2022-01-01 2022-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001701541 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001701541 us-gaap:CommonStockMember 2022-03-31 0001701541 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001701541 us-gaap:RetainedEarningsMember 2022-03-31 0001701541 2022-03-31 0001701541 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001701541 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001701541 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001701541 us-gaap:CommonStockMember 2022-06-30 0001701541 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001701541 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001701541 us-gaap:RetainedEarningsMember 2022-06-30 0001701541 srt:MaximumMember srt:ScenarioForecastMember bdtx:OpenMarketSaleMember 2022-07-01 2022-09-30 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-06-30 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-06-30 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-06-30 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-06-30 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001701541 us-gaap:FairValueMeasurementsRecurringMember 2022-06-30 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2021-12-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001701541 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001701541 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001701541 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001701541 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001701541 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-06-30 0001701541 us-gaap:CorporateBondSecuritiesMember 2022-06-30 0001701541 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2022-06-30 0001701541 us-gaap:CorporateBondSecuritiesMember 2021-12-31 0001701541 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-12-31 0001701541 2021-01-01 2021-12-31 0001701541 us-gaap:EquipmentMember 2022-06-30 0001701541 us-gaap:EquipmentMember 2021-12-31 0001701541 us-gaap:FurnitureAndFixturesMember 2022-06-30 0001701541 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001701541 us-gaap:OfficeEquipmentMember 2022-06-30 0001701541 us-gaap:OfficeEquipmentMember 2021-12-31 0001701541 us-gaap:LeaseholdImprovementsMember 2022-06-30 0001701541 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001701541 us-gaap:ConstructionInProgressMember 2022-06-30 0001701541 us-gaap:ConstructionInProgressMember 2021-12-31 0001701541 bdtx:A2020StockOptionPlanMember 2020-01-14 0001701541 bdtx:A2020StockOptionPlanMember 2022-01-01 2022-01-01 0001701541 bdtx:A2020StockOptionPlanMember 2022-01-01 0001701541 bdtx:A2020EmployeeStockPurchasePlanMember 2020-01-14 0001701541 bdtx:A2020EmployeeStockPurchasePlanMember 2022-01-01 2022-01-01 0001701541 us-gaap:EmployeeStockOptionMember 2022-04-01 2022-06-30 0001701541 us-gaap:EmployeeStockOptionMember 2021-04-01 2021-06-30 0001701541 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001701541 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2022-04-01 2022-06-30 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2021-04-01 2021-06-30 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2022-01-01 2022-06-30 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001701541 bdtx:OtherAwardTypeMember 2022-04-01 2022-06-30 0001701541 bdtx:OtherAwardTypeMember 2021-04-01 2021-06-30 0001701541 bdtx:OtherAwardTypeMember 2022-01-01 2022-06-30 0001701541 bdtx:OtherAwardTypeMember 2021-01-01 2021-06-30 0001701541 us-gaap:EmployeeStockOptionMember bdtx:A2020StockOptionPlanMember 2022-01-01 2022-06-30 0001701541 us-gaap:ResearchAndDevelopmentExpenseMember 2022-04-01 2022-06-30 0001701541 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001701541 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-06-30 0001701541 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001701541 us-gaap:GeneralAndAdministrativeExpenseMember 2022-04-01 2022-06-30 0001701541 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001701541 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-06-30 0001701541 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001701541 us-gaap:RestrictedStockMember 2021-12-31 0001701541 us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001701541 us-gaap:RestrictedStockMember 2022-06-30 0001701541 us-gaap:RestrictedStockUnitsRSUMember 2022-06-30 0001701541 bdtx:PerformanceRestrictedStockUnitsMember 2022-01-01 2022-06-30 0001701541 bdtx:PerformanceRestrictedStockUnitsMember 2022-06-30 0001701541 us-gaap:EmployeeStockMember bdtx:A2020EmployeeStockPurchasePlanMember 2022-01-01 2022-06-30 0001701541 us-gaap:EmployeeStockMember bdtx:A2020EmployeeStockPurchasePlanMember 2022-06-30 0001701541 us-gaap:EmployeeStockMember bdtx:A2020EmployeeStockPurchasePlanMember 2021-01-01 2021-06-30 0001701541 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-06-30 0001701541 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-06-30 0001701541 us-gaap:RestrictedStockMember 2022-01-01 2022-06-30 0001701541 us-gaap:RestrictedStockMember 2021-01-01 2021-06-30 0001701541 us-gaap:EmployeeStockMember 2022-01-01 2022-06-30 0001701541 us-gaap:EmployeeStockMember 2021-01-01 2021-06-30 0001701541 us-gaap:WarrantMember 2022-01-01 2022-06-30 0001701541 us-gaap:WarrantMember 2021-01-01 2021-06-30 0001701541 bdtx:OperatingLeasePrincipalOfficeTwoMember 2020-07-31 0001701541 bdtx:OperatingLeasePrincipalOfficeOneMember 2019-02-28 0001701541 2021-06-15 2021-06-15 0001701541 bdtx:OperatingLeaseOfficeAndLaboratorySpaceNYMember 2020-12-31 shares iso4217:USD iso4217:USD shares pure bdtx:contract utr:sqft false Q2 2022 0001701541 --12-31 http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent P5Y P3Y P5Y 10-Q true 2022-06-30 false 001-38501 BLACK DIAMOND THERAPEUTICS, INC. DE 81-4254660 One Main Street, 14th Floor Cambridge MA 02142 (617) 252-0848 Common stock, par value $0.0001 BDTX NASDAQ Yes Yes Non-accelerated Filer true true false false 36339466 55877000 65799000 105013000 143987000 7668000 5917000 168558000 215703000 2873000 3035000 1168000 1223000 26225000 27705000 10000 16000 198834000 247682000 2222000 4107000 17484000 19535000 19706000 23642000 26757000 28140000 46463000 51782000 0 0 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 500000000 500000000 36315737 36315737 36234624 36234624 5000 5000 446909000 440129000 -2286000 -414000 -292257000 -243820000 152371000 195900000 198834000 247682000 16195000 26719000 33981000 49539000 6978000 7996000 14871000 15889000 23173000 34715000 48852000 65428000 -23173000 -34715000 -48852000 -65428000 386000 948000 792000 2100000 -143000 -584000 -377000 -1324000 243000 364000 415000 776000 -22930000 -34351000 -48437000 -64652000 -0.63 -0.63 -0.95 -0.95 -1.33 -1.33 -1.79 -1.79 36293856 36293856 36182541 36182541 36282636 36282636 36152942 36152942 -22930000 -34351000 -48437000 -64652000 -511000 -124000 -1872000 -403000 -23441000 -34475000 -50309000 -65055000 -48437000 -64652000 6627000 7652000 253000 39000 -365000 -1326000 1371000 748000 0 14000 -3000 0 1751000 2956000 -6000 -8000 -1885000 1635000 -1836000 7355000 -1383000 -761000 -46667000 -49620000 200000 888000 57241000 95138000 20504000 42576000 36537000 51674000 153000 665000 153000 665000 -9977000 2719000 67022000 35828000 57045000 38547000 55877000 37324000 1168000 1223000 57045000 38547000 0 1199000 109000 5717000 0 476000 36078383 5000 425363000 614000 -118224000 307758000 62607 481000 481000 4998 1224 3094000 3094000 -279000 -279000 -30301000 -30301000 36147212 5000 428938000 335000 -148525000 280753000 48014 184000 184000 8331 2269 4558000 4558000 -124000 -124000 -34351000 -34351000 36205826 5000 433680000 211000 -182876000 251020000 36234624 5000 440129000 -414000 -243820000 195900000 3565 11000 11000 5000 31341 142000 142000 13038 3375000 3375000 -1361000 -1361000 -25507000 -25507000 36287568 5000 443657000 -1775000 -269327000 172560000 3333 24836 3252000 3252000 -511000 -511000 -22930000 -22930000 36315737 36315737 5000 446909000 -2286000 -292257000 152371000 NATURE OF BUSINESS AND BASIS OF PRESENTATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the “Company”) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of its mutation, allostery, and pharmacology computational and drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On February 1, 2021, the Company filed a shelf registration statement on Form S-3 ASR (the “Shelf”), with the Securities and Exchange Commission (the “SEC”), which covers the offering, issuance and sale of the Company’s common stock, preferred stock, debt securities, warrants and/or units of any combination thereof. The Company simultaneously entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> with Jefferies LLC, as sales agent, to provide for the issuance and sale by the Company of up to $150 million of its common stock from time to time through Jefferies as its sales agent (the “ATM Program”). The Shelf became automatically effective upon filing on February 1, 2021. As of June 30, 2022, no sales have been made pursuant to the ATM Program.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared on the basis of continuity of operations, realization of assets, and the satisfaction of liabilities and commitments in the ordinary course of business. Historically, the Company has funded its operations primarily with proceeds from the sale of preferred and common stock. The Company expects to continue to generate operating losses for the foreseeable future. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of August 9, 2022, the issuance date of the condensed consolidated financial statements, the Company expects that its cash, cash equivalents and investments will be sufficient to fund its currently planned operations for at least the next 12 months from the filing date of these unaudited interim condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company may seek additional funding through private or public equity financings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into collaborations or other arrangements. The terms of any financing may adversely affect the holdings or the rights of the Company's stockholders. If the Company is unable to obtain funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect its business prospects. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The ongoing COVID-19 pandemic is evolving, and to date has led to the implementation of various responses, including government-imposed quarantines, travel restrictions, and other public health safety measures.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has been closely monitoring the impact of the ongoing COVID-19 pandemic on all aspects of the Company’s business, including how it has impacted and may continue to impact the Company’s operations and the operations of its suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, the Company has taken steps to minimize the current environment’s impact on its business and strategy, including devising contingency plans and securing additional resources from third party service providers. Furthermore, for the safety of the Company’s employees and families, the Company has introduced enhanced safety measures for scientists to be present in its labs and increased the use of third party service providers for the conduct of certain experiments and studies for research programs. Certain of the Company’s third party service providers have also experienced shutdowns or other business disruptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The extent to which COVID-19 ultimately impacts the Company’s business, results of operations or financial condition will depend on future developments, which, despite progress in vaccination efforts, remain highly uncertain and cannot be predicted with confidence, such as the duration of the COVID-19 pandemic, new strains of the virus, including any future variants that may emerge, which may impact rates of infection and vaccination efforts, developments or perceptions regarding the safety of vaccines, new information that may emerge concerning the severity of COVID-19, and any additional preventative and protective actions taken to contain the pandemic or treat its impact, among others. The Company does not yet know the full extent of potential delays or impacts on the Company’s business, clinical trials, research programs, healthcare systems or the global economy and cannot presently predict the scope and severity of any potential business shutdowns or disruptions but if the Company or any of the third parties with whom it engages were to experience prolonged business shutdowns or other disruptions, the Company’s ability to conduct its business in the manner and on the timelines presently planned could be materially and negatively affected, which could have a material adverse impact on the Company’s business, results of operations and financial condition. The estimates of the impact on the Company’s business may change based on new information that may emerge concerning COVID-19 and the actions to contain it or treat its impact and the economic impact on local, regional, national and international markets.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Black Diamond Therapeutics, Inc. (the “Company”) is a precision oncology medicine company pioneering the discovery and development of MasterKey therapies. The Company was originally organized as a limited liability company in December 2014 under the name ASET Therapeutics LLC. In September 2016, the Company was converted to a corporation under the laws of the State of Delaware under the name ASET Therapeutics, Inc. The Company changed its name to Black Diamond Therapeutics, Inc. in January 2018. Since its inception, the Company has devoted substantially all of its efforts to raising capital, obtaining financing, and incurring research and development costs related to the development of its mutation, allostery, and pharmacology computational and drug discovery engine. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s technology will be obtained, that any products developed will obtain necessary government regulatory approval or that any products, if approved, will be commercially viable. The Company operates in an environment of rapid technological innovation and substantial competition from pharmaceutical and biotechnological companies. In addition, the Company is dependent upon the services of its employees, consultants and service providers. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div> 150000000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following is a summary of significant accounting policies followed in the preparation of these condensed consolidated financial statements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Principles of consolidation </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Unaudited interim financial information</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of the Company included herein have been prepared, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this Quarterly Report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report. In the opinion of the Company’s management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair statement of the results for the interim periods presented have been included.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Use of estimates </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The full extent to which the ongoing COVID-19 pandemic will directly or indirectly impact the Company’s business, results of operations and financial condition, including expenses, research and development costs and employee-related amounts, will depend on future developments that are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19, as well as the economic impact on local, regional, national and international markets. The Company has considered the impact of COVID-19 on estimates within its financial statements and there may be changes to those estimates in future periods. As of the date of issuance of these condensed consolidated financial statements, the Company has not experienced material business disruptions or incurred impairment losses in the carrying value of its assets as a result of the pandemic and is not aware of any specific related event or circumstance that would require it to update its estimates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company believes that no recently issued accounting standards will have a material impact on its condensed consolidated financial statements, or apply to its operations.</span></div> Principles of consolidation The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") and include the accounts of the Company and its wholly owned subsidiaries, Black Diamond Therapeutics (Canada), Inc. and Black Diamond Therapeutics Security Corporation, after elimination of all significant intercompany accounts and transactions. Use of estimates The preparation of the Company’s condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual of research and development expenses and the valuation of stock-based awards. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results may differ from those estimates or assumptions. <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Recently issued accounting pronouncements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company believes that no recently issued accounting standards will have a material impact on its condensed consolidated financial statements, or apply to its operations.</span></div> FAIR VALUE MEASUREMENTS<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at June 30, 2022 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">53,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">53,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">53,761 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">105,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">158,774 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2021 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">143,987 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">207,717 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">When developing fair value estimates, the Company maximizes the use of observable inputs and minimizes the use of unobservable inputs. When available, the Company uses quoted market prices to measure fair value. The valuation technique used to measure fair value for the Company's Level 1 and Level 2 assets is a market approach, using prices and other relevant information generated by market transactions involving identical or comparable assets. If market prices are not available, the fair value measurement is based on models that use primarily market-based parameters including yield curves, volatilities, credit ratings and currency rates. In certain cases where market rate assumptions are not available, the Company is required to make judgments about assumptions market participants would use to estimate the fair value of a financial instrument. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">There were no transfers in or out of Level 3 categories in the periods presented.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following tables present information about the Company’s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy used to determine such fair values: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at June 30, 2022 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">53,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">53,761 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,542 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">53,761 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">105,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">158,774 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value measurements at December 31, 2021 using:</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63,730 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">143,987 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">207,717 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 53761000 0 0 53761000 0 14542000 0 14542000 0 51487000 0 51487000 0 38984000 0 38984000 53761000 105013000 0 158774000 63730000 0 0 63730000 0 104066000 0 104066000 0 39921000 0 39921000 63730000 143987000 0 207717000 INVESTMENTS<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2022, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">107,299 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,286)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">105,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2021, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">144,401 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(461)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">143,987 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2022, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $47,880 that had maturities of one to three years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2021, all marketable securities held by the Company had remaining contractual maturities of one year or less, except for U.S. government agencies and corporate bonds with a fair value of $86,187 that had maturities of one to three years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2022, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies, corporate bonds and commercial paper with a fair value of $47,880, that had maturities of one to three years. As of December 31, 2021, the marketable securities in a loss position had a maturity of less than one year, except for U.S. government agencies and corporate bonds, with a fair value of $86,187, that had maturities of one to three years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2022, the Company reviewed its investment portfolio to assess whether the unrealized losses on its available-for-sale investments were temporary. In determining whether the decline in fair value of these securities was temporary, the Company evaluated whether it intended to sell the security and whether it was more likely than not that the Company would be required to sell the security before recovering its amortized cost basis. There have been no impairments of the Company’s assets measured and carried at fair value during the six months ended June 30, 2022 and the year ended December 31, 2021.</span></div> <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2022, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,547 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,542 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52,620 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,132 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,148)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38,984 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">107,299 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,286)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">105,013 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2021, investments were comprised of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.198%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.398%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Corporate bonds</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,261 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">104,066 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">U.S. Government agencies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40,140 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(219)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,921 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">144,401 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">47 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(461)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">143,987 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 14547000 0 5000 14542000 52620000 0 1133000 51487000 40132000 0 1148000 38984000 107299000 0 2286000 105013000 104261000 47000 242000 104066000 40140000 0 219000 39921000 144401000 47000 461000 143987000 47880000 86187000 47880000 86187000 0 0 PROPERTY AND EQUIPMENT<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,456 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,404 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,035 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense for the six months ended June 30, 2022 and 2021 was $253 and $39, respectively.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment, net consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">807 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">682 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer and office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Construction in process</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,456 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,404 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(583)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(369)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total Property and Equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,873 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,035 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 807000 682000 17000 17000 120000 120000 2512000 2437000 0 148000 3456000 3404000 583000 369000 2873000 3035000 253000 39000 ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,088 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1NmViMGU1YzZkZjRkYjJhNjMyZTBkNDgyYWNlMzdjL3NlYzphNTZlYjBlNWM2ZGY0ZGIyYTYzMmUwZDQ4MmFjZTM3Y180Ni9mcmFnOmM3OWVjOTI2MzY0NjQ1OThiNzIzNzc5MDI1YWI0OGRhL3RhYmxlOmMyMzk0OGEwNGUwNDQzYTVhNWFiZTI2YmEwMDY3ODA1L3RhYmxlcmFuZ2U6YzIzOTQ4YTA0ZTA0NDNhNWE1YWJlMjZiYTAwNjc4MDVfNC0wLTEtMS0xOTAzMA_449d2104-8e72-4c1e-b709-389e28fc5d09"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1NmViMGU1YzZkZjRkYjJhNjMyZTBkNDgyYWNlMzdjL3NlYzphNTZlYjBlNWM2ZGY0ZGIyYTYzMmUwZDQ4MmFjZTM3Y180Ni9mcmFnOmM3OWVjOTI2MzY0NjQ1OThiNzIzNzc5MDI1YWI0OGRhL3RhYmxlOmMyMzk0OGEwNGUwNDQzYTVhNWFiZTI2YmEwMDY3ODA1L3RhYmxlcmFuZ2U6YzIzOTQ4YTA0ZTA0NDNhNWE1YWJlMjZiYTAwNjc4MDVfNC0wLTEtMS0xOTAzMA_933990b4-2bcd-4530-b17a-bbbb2f4225a2">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,484 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,535 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.888%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.118%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30,<br/>2022</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">December 31,<br/>2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Contracted research services</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,072 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,192 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Payroll and related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,088 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Professional and consulting fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">971 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,935 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1NmViMGU1YzZkZjRkYjJhNjMyZTBkNDgyYWNlMzdjL3NlYzphNTZlYjBlNWM2ZGY0ZGIyYTYzMmUwZDQ4MmFjZTM3Y180Ni9mcmFnOmM3OWVjOTI2MzY0NjQ1OThiNzIzNzc5MDI1YWI0OGRhL3RhYmxlOmMyMzk0OGEwNGUwNDQzYTVhNWFiZTI2YmEwMDY3ODA1L3RhYmxlcmFuZ2U6YzIzOTQ4YTA0ZTA0NDNhNWE1YWJlMjZiYTAwNjc4MDVfNC0wLTEtMS0xOTAzMA_449d2104-8e72-4c1e-b709-389e28fc5d09"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1NmViMGU1YzZkZjRkYjJhNjMyZTBkNDgyYWNlMzdjL3NlYzphNTZlYjBlNWM2ZGY0ZGIyYTYzMmUwZDQ4MmFjZTM3Y180Ni9mcmFnOmM3OWVjOTI2MzY0NjQ1OThiNzIzNzc5MDI1YWI0OGRhL3RhYmxlOmMyMzk0OGEwNGUwNDQzYTVhNWFiZTI2YmEwMDY3ODA1L3RhYmxlcmFuZ2U6YzIzOTQ4YTA0ZTA0NDNhNWE1YWJlMjZiYTAwNjc4MDVfNC0wLTEtMS0xOTAzMA_933990b4-2bcd-4530-b17a-bbbb2f4225a2">Current portion of operating lease liability</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,089 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,484 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,535 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 11072000 12192000 3352000 5088000 971000 1935000 2089000 320000 17484000 19535000 STOCK-BASED COMPENSATION<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Stock Option and Incentive Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Stock Option and Incentive Plan (the “2020 Plan”) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020 and became effective on the date immediately prior to the date on which the registration statement for the Company’s initial public offering (“IPO”) was declared effective. The 2020 Plan provides for the grant of incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, restricted stock awards, unrestricted stock awards, cash-based awards and dividend equivalent rights to the Company’s officers, employees, directors and consultants. The 2020 Plan provides for an annual increase, to be added on the first day of each fiscal year, by up to 4% of the Company’s outstanding shares of common stock as of the last day of the prior year. On January 1, 2022, 1,449,384 shares of common stock, representing 4% of the Company’s outstanding shares of common stock as of December 31, 2021, were added to the 2020 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (the “2020 ESPP”) was approved by the Company’s board of directors on December 5, 2019, and the Company’s stockholders on January 14, 2020, and became effective on the date immediately prior to the date on which the registration statement for the Company’s IPO was declared effective. The 2020 ESPP provides for an annual increase, to be added on the first day of each fiscal year, by up to 1% of the number of shares of the Company’s common stock outstanding on the immediately preceding December 31. The number of authorized shares reserved for issuance under the 2020 ESPP was increased by 326,364 shares effective as of January 1, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three Months Ended<br/>June 30,</td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,252 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,558 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,652 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, the Company issued 37,874 shares of common stock out of its 2020 Plan under its policy where non-employee directors may elect to receive their compensation in the form of common stock in lieu of cash.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>June 30,</td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,726 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,324 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,573 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,798 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,252 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,627 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,652 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Options </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company’s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:46.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exercise</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,903,839 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,816,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(691,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,025,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options vested or expected to vest at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,025,594 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,478,157 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, total unrecognized compensation cost related to the unvested stock-options was $23,832, which is expected to be recognized over a weighted average period of 2.2 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Restricted stock units </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The fair values of restricted stock units are based on the market value of the Company’s stock on the date of the grant. Under terms of the time-based restricted stock agreements covering the common stock, shares of restricted common stock are subject to a vesting schedule. The following table summarizes time-based restricted stock activity since January 1, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number of</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">average</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">grant date</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">fair value</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29.53 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">185,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29.24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">208,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The total fair value of time-based restricted stock units vested during the six months ended June 30, 2022 was $244. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, total unrecognized compensation cost related to the time-based unvested restricted stock units was $757, which is expected to be recognized over a weighted average period of 1.3 years.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, the Company granted to its employees 55,125 performance restricted stock units related to the achievement of certain clinical development and/or financing milestones. As of June 30, 2022, the Company had 267,125 performance restricted stock units outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Recognition of stock-based compensation expense associated with performance restricted stock units commences when the performance conditions are considered probable of achievement, using management’s best estimates, which consider the inherent risk and uncertainty regarding the future outcomes of the milestones.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2022, for performance-based restricted stock units that were outstanding, the achievement of the milestones that had not been met was considered not probable, and therefore no expense has been recognized related to these awards in the six months ended June 30, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Employee stock purchase plan</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The 2020 ESPP enables eligible employees to purchase shares of the Company's common stock at the end of each six-month offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower. Eligible employees generally included all employees. Offering periods begin on the first trading day of January and July of each year and end on the last trading day in June and December of each year, except for the first offering period which began on the first trading day in March and ended on the last trading day in June. Share purchases are funded through payroll deductions of up to 10% of an employee’s eligible compensation for each payroll period, up to $25 each calendar year.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022 and 2021, there were 31,341 and no shares, respectively, issued under the 2020 ESPP.</span></div> 0.04 1449384 0.04 0.01 326364 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following award type categories included within the condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top">Three Months Ended<br/>June 30,</td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,000 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,193 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">290 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">310 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Employee Stock Purchase Plan and Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">124 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,252 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,558 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,627 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,652 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its condensed consolidated statements of operations and comprehensive loss:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended<br/>June 30,</td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,526 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,234 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,054 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,854 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,726 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,324 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,573 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,798 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,252 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,558 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,627 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,652 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3000000 4216000 6193000 7010000 189000 290000 310000 560000 63000 52000 124000 82000 3252000 4558000 6627000 7652000 37874 1526000 2234000 3054000 3854000 1726000 2324000 3573000 3798000 3252000 4558000 6627000 7652000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the Company’s equity awards plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:46.951%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.454%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Exercise</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Price</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in Years)</span></div></td><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:139%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,903,839 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17.38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">847 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,816,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3,565)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cancelled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(691,330)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Outstanding June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,025,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options vested or expected to vest at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,025,594 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">289 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,478,157 </span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 4903839 17.38 P7Y7M6D 847000 1816650 3.33 3565 3.20 691330 16.50 6025594 13.25 P8Y 289000 6025594 13.25 P8Y 289000 2478157 16.05 P6Y10M24D 45000 23832000 P2Y2M12D The following table summarizes time-based restricted stock activity since January 1, 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number of</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">shares</span></div></td><td colspan="3" style="border-top:2pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">average</span></div><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">grant date</span></div><div style="margin-bottom:0.75pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">fair value</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,667 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29.53 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">185,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2.32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8,333)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29.24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unvested restricted common stock as of June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">208,129 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 30667 29.53 185795 2.32 8333 29.24 208129 5.25 244000 757000 P1Y3M18D 55125 267125 0 P6M 0.85 0.10 25000 31341 0 NET LOSS PER SHARE<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Net loss per share</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(22,930)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(34,351)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(48,437)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(64,652)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,293,856 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,182,541 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,282,636 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,152,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.63)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.95)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1.33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1.79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company’s potentially dilutive securities, which include options, unvested restricted stock and warrants to purchase common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,025,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,209,744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">208,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,272,052 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,274,448 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table summarizes the computation of basic and diluted net loss per share of the Company (in thousands, except share and per share amounts):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.403%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(22,930)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(34,351)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(48,437)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(64,652)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted average common shares outstanding, basic and diluted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,293,856 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,182,541 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,282,636 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,152,942 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.63)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(0.95)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1.33)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1.79)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> -22930000 -34351000 -48437000 -64652000 36293856 36293856 36182541 36182541 36282636 36282636 36152942 36152942 -0.63 -0.63 -0.95 -0.95 -1.33 -1.33 -1.79 -1.79 The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.175%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.977%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,025,594 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,209,744 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">208,129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">51,007 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Shares issuable under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">27,572 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,757 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><div style="margin-bottom:2pt;margin-top:2pt"><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,272,052 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,274,448 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 6025594 5209744 208129 51007 27572 2940 10757 10757 6272052 5274448 LEASES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has historically entered into lease arrangements for its facilities. As of June 30, 2022, the Company had two operating leases with required future minimum payments. The Company determined the classification of these leases to be operating leases and recorded right-of-use assets and lease liabilities as of the effective dates. The Company’s leases generally do not include termination or purchase options. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Operating leases </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In July 2020, the Company entered into a seven-year agreement with an option to extend for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1NmViMGU1YzZkZjRkYjJhNjMyZTBkNDgyYWNlMzdjL3NlYzphNTZlYjBlNWM2ZGY0ZGIyYTYzMmUwZDQ4MmFjZTM3Y181NS9mcmFnOjc4YjA2ZmU0MDk3MzRjZDk5YTc1NWQzMGRiMGZhZGM0L3RleHRyZWdpb246NzhiMDZmZTQwOTczNGNkOTlhNzU1ZDMwZGIwZmFkYzRfNTMw_baca8b1c-1bf3-4621-a694-2fc94fbde5a4">five</span> additional years to lease two floors totaling approximately 25,578 square feet of office space for its principal office, which is located in Cambridge, MA. The lease on the first floor commenced on August 1, 2020 and the lease on the second floor commenced March 9, 2021. The Company recognized the respective lease balances on the condensed consolidated balance sheets when the lease of each floor commenced. Under the terms of the lease, the Company was required to issue a $1,168 letter of credit as security for the lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company previously leased an office space in Cambridge, MA under a lease that commenced in February 2019 for approximately 2,357 square feet of office space, which was set to expire on April 30, 2022, subject to an option to extend the lease for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1NmViMGU1YzZkZjRkYjJhNjMyZTBkNDgyYWNlMzdjL3NlYzphNTZlYjBlNWM2ZGY0ZGIyYTYzMmUwZDQ4MmFjZTM3Y181NS9mcmFnOjc4YjA2ZmU0MDk3MzRjZDk5YTc1NWQzMGRiMGZhZGM0L3RleHRyZWdpb246NzhiMDZmZTQwOTczNGNkOTlhNzU1ZDMwZGIwZmFkYzRfMTI5OQ_eea55c4d-e0cf-4b8b-a058-a5c18c4400a9">three</span> additional years. Effective June 15, 2021, the lease was terminated, and the remaining right-of-use asset and lease liability were derecognized. A gain of $5 was recognized for the termination of the lease.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In December 2020, the Company entered into an eleven-year agreement to lease approximately 18,120 square feet of office and laboratory space in New York, NY. The Company has an option to extend the lease for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE1NmViMGU1YzZkZjRkYjJhNjMyZTBkNDgyYWNlMzdjL3NlYzphNTZlYjBlNWM2ZGY0ZGIyYTYzMmUwZDQ4MmFjZTM3Y181NS9mcmFnOjc4YjA2ZmU0MDk3MzRjZDk5YTc1NWQzMGRiMGZhZGM0L3RleHRyZWdpb246NzhiMDZmZTQwOTczNGNkOTlhNzU1ZDMwZGIwZmFkYzRfMTY5OA_09591961-d0ea-4502-acff-c3f5505f258f">five</span> additional years. The lease commenced August 26, 2021 and the related lease balance was recognized on the condensed consolidated balance sheet.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,297 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">944 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,632 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,726 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">732 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The variable lease costs for the three and six months ended June 30, 2022 and 2021 include common area maintenance and other operating charges. As the Company’s leases do not provide an implicit rate, the Company utilized its incremental borrowing rate to discount lease payments, which reflects the fixed rate at which the Company could borrow on a collateralized basis the amount of the lease payments in the same currency, for a similar term, in a similar economic environment.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company’s operating leases as of June 30, 2022 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of June 30, 2022</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022 (excluding the six months ended June 30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,846 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 2 P7Y 25578 1168000 2357 5000 P11Y 18120 <div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company’s operating lease for the three and six months ended June 30, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.877%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.974%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.979%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended June 30,</td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">613 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,075 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Short-term lease cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">288 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">40 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">575 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">476 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">76 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,297 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">944 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,632 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,726 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.256%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.434%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.436%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Operating Lease Information</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">June 30, 2021</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liability</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,290 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">732 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8.3</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7.1</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 1057000 613000 2116000 1075000 21000 288000 40000 575000 219000 43000 476000 76000 1297000 944000 2632000 1726000 1290000 732000 P8Y3M18D P7Y1M6D 0.053 0.053 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum lease payments under the Company’s operating leases as of June 30, 2022 were as follows: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.480%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.320%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom">As of June 30, 2022</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2022 (excluding the six months ended June 30, 2022)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,460 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,359 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,477 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,599 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">36,112 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(7,266)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,846 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 1460000 4244000 4359000 4477000 4599000 16973000 36112000 7266000 28846000 COMMITMENTS AND CONTINGENCIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company enters into contracts in the normal course of business with contract research organizations ("CROs"), contract manufacturing organizations ("CMOs") and other third parties for preclinical research studies, clinical trials and testing and manufacturing services. These contracts do not contain minimum purchase commitments and are cancelable upon prior written notice. Payments due upon cancellation consist only of payments for services provided or expenses incurred, including noncancelable obligations of service providers, up to the date of cancellation.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">License agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is a party to license agreements, which include contingent payments. These payments will become payable if and when certain development, regulatory and commercial milestones are achieved. As of June 30, 2022, the satisfaction and timing of the contingent payments is uncertain and not reasonably estimable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Indemnification agreements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors and executive officers that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnifications. The Company is not aware of any indemnification arrangements that could have a material effect on its financial position, results of operations or cash flows, and it has not accrued any liabilities related to such obligations in its consolidated financial statements as of June 30, 2022 or December 31, 2021. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Legal proceedings</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not currently party to and is not aware of any material legal proceedings. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related to such legal proceedings.</span></div> BENEFIT PLANSThe Company has a tax-qualified 401(k) and Profit Sharing defined contribution plan (the “401(k) Plan”). Under the 401(k) Plan, the Company provides an employer safe harbor matching contribution equal to 100% of a participant’s eligible contributions of up to 6% of eligible compensation, subject to limits established by the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). All matching contributions are fully vested when made. During the three and six months ended June 30, 2022 and 2021, the Company contributed $199, $757, $220 and $565, respectively, to the 401(k) Plan. 1 0.06 199000 757000 220000 565000 EXCEL 53 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO=V]R:W-H965T&UL4$L! A0#% @ U#L)59#39"+/ @ XP< !D M ("!JMD 'AL+W=O&PO M=V]R:W-H965T>,0, M / 2 - " >O? !X;"]S='EL97,N>&UL4$L! A0#% M @ U#L)59>*NQS $P( L ( !1^, %]R96QS+RYR M96QS4$L! A0#% @ U#L)56&W17;> P GQL \ ( ! M,.0 'AL+W=O7!E&UL4$L%!@ Q #$ 3@T -SK $! end XML 54 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 55 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2 html 153 209 1 false 37 0 false 6 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.blackdiamondtherapeutics.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (Unaudited) Statements 2 false false R3.htm 1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Sheet http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (Unaudited) Statements 6 false false R7.htm 2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION Sheet http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION NATURE OF BUSINESS AND BASIS OF PRESENTATION Notes 7 false false R8.htm 2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 2105103 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 9 false false R10.htm 2108104 - Disclosure - INVESTMENTS Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTS INVESTMENTS Notes 10 false false R11.htm 2112105 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT PROPERTY AND EQUIPMENT Notes 11 false false R12.htm 2115106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Sheet http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Notes 12 false false R13.htm 2118107 - Disclosure - STOCK-BASED COMPENSATION Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION STOCK-BASED COMPENSATION Notes 13 false false R14.htm 2124108 - Disclosure - NET LOSS PER SHARE Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE NET LOSS PER SHARE Notes 14 false false R15.htm 2128109 - Disclosure - LEASES Sheet http://www.blackdiamondtherapeutics.com/role/LEASES LEASES Notes 15 false false R16.htm 2133110 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 16 false false R17.htm 2134111 - Disclosure - BENEFIT PLANS Sheet http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS BENEFIT PLANS Notes 17 false false R18.htm 2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 18 false false R19.htm 2306301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS 19 false false R20.htm 2309302 - Disclosure - INVESTMENTS (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables INVESTMENTS (Tables) Tables http://www.blackdiamondtherapeutics.com/role/INVESTMENTS 20 false false R21.htm 2313303 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT 21 false false R22.htm 2316304 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables) Tables http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES 22 false false R23.htm 2319305 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables STOCK-BASED COMPENSATION (Tables) Tables http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION 23 false false R24.htm 2325306 - Disclosure - NET LOSS PER SHARE (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables NET LOSS PER SHARE (Tables) Tables http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE 24 false false R25.htm 2329307 - Disclosure - LEASES (Tables) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESTables LEASES (Tables) Tables http://www.blackdiamondtherapeutics.com/role/LEASES 25 false false R26.htm 2402401 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) Sheet http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details) Details http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION 26 false false R27.htm 2407402 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Sheet http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) Details 27 false false R28.htm 2410403 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details) Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails INVESTMENTS - Schedule of Marketable Securities (Details) Details 28 false false R29.htm 2411404 - Disclosure - INVESTMENTS - Additional Information (Details) Sheet http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails INVESTMENTS - Additional Information (Details) Details 29 false false R30.htm 2414405 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails PROPERTY AND EQUIPMENT (Details) Details http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables 30 false false R31.htm 2417406 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Sheet http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) Details http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables 31 false false R32.htm 2420407 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails STOCK-BASED COMPENSATION - Narrative (Details) Details 32 false false R33.htm 2421408 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details) Details 33 false false R34.htm 2422409 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) Details 34 false false R35.htm 2423410 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) Sheet http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details) Details 35 false false R36.htm 2426411 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details) Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails NET LOSS PER SHARE - Computation of Net Loss per Share (Details) Details 36 false false R37.htm 2427412 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) Sheet http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details) Details 37 false false R38.htm 2430413 - Disclosure - LEASES - Narrative (Details) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails LEASES - Narrative (Details) Details 38 false false R39.htm 2431414 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails LEASES - Summary of Lease Cost and Other Operating Lease Information (Details) Details 39 false false R40.htm 2432415 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details) Sheet http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails LEASES - Schedule of Future Minimum Lease Payments (Details) Details 40 false false R41.htm 2435416 - Disclosure - BENEFIT PLANS (Details) Sheet http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails BENEFIT PLANS (Details) Details http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS 41 false false All Reports Book All Reports bdtx-20220630.htm bdtx-20220630.xsd bdtx-20220630_cal.xml bdtx-20220630_def.xml bdtx-20220630_lab.xml bdtx-20220630_pre.xml blackdiamond-executiveempl.htm exhibit311_q22022.htm exhibit312_q22022.htm exhibit321_q22022.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 59 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "bdtx-20220630.htm": { "axisCustom": 0, "axisStandard": 13, "contextCount": 153, "dts": { "calculationLink": { "local": [ "bdtx-20220630_cal.xml" ] }, "definitionLink": { "local": [ "bdtx-20220630_def.xml" ] }, "inline": { "local": [ "bdtx-20220630.htm" ] }, "labelLink": { "local": [ "bdtx-20220630_lab.xml" ] }, "presentationLink": { "local": [ "bdtx-20220630_pre.xml" ] }, "schema": { "local": [ "bdtx-20220630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 329, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 5, "http://xbrl.sec.gov/dei/2022": 5, "total": 10 }, "keyCustom": 11, "keyStandard": 198, "memberCustom": 8, "memberStandard": 26, "nsprefix": "bdtx", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.blackdiamondtherapeutics.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2108104 - Disclosure - INVESTMENTS", "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS", "shortName": "INVESTMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112105 - Disclosure - PROPERTY AND EQUIPMENT", "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2115106 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118107 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124108 - Disclosure - NET LOSS PER SHARE", "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE", "shortName": "NET LOSS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2128109 - Disclosure - LEASES", "role": "http://www.blackdiamondtherapeutics.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133110 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2134111 - Disclosure - BENEFIT PLANS", "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS", "shortName": "BENEFIT PLANS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)", "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "shortName": "Condensed Consolidated Balance Sheets (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2309302 - Disclosure - INVESTMENTS (Tables)", "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables", "shortName": "INVESTMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313303 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316304 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319305 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325306 - Disclosure - NET LOSS PER SHARE (Tables)", "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables", "shortName": "NET LOSS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2329307 - Disclosure - LEASES (Tables)", "role": "http://www.blackdiamondtherapeutics.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i5d271eec4f3543f8a823ac3aa291895f_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i5d271eec4f3543f8a823ac3aa291895f_D20220701-20220930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:SaleOfStockConsiderationReceivedOnTransaction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ifea6c25d4ad143d89a265b9256a00717_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ifea6c25d4ad143d89a265b9256a00717_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - INVESTMENTS - Schedule of Marketable Securities (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails", "shortName": "INVESTMENTS - Schedule of Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - INVESTMENTS - Additional Information (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails", "shortName": "INVESTMENTS - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bdtx:DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414405 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails", "shortName": "PROPERTY AND EQUIPMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bdtx:AccruedContractResearchServiceFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417406 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "bdtx:AccruedContractResearchServiceFeesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420407 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i78a311fe5a234d5dbd14179a444d66b0_I20220101", "decimals": "2", "lang": "en-US", "name": "bdtx:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ie6cd355ead2d42fda29fafd7e1c87f75_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421408 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "iacbde7e426294e9288b335255ba29f7c_D20220401-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ie0fd036eb4284d148e0dcf753041dc95_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422409 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": "0", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ieb29777f7cc74396a00299688e888559_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423410 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "shortName": "STOCK-BASED COMPENSATION - Schedule of Restricted Stock Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ieb29777f7cc74396a00299688e888559_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ie6cd355ead2d42fda29fafd7e1c87f75_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426411 - Disclosure - NET LOSS PER SHARE - Computation of Net Loss per Share (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails", "shortName": "NET LOSS PER SHARE - Computation of Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427412 - Disclosure - NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "shortName": "NET LOSS PER SHARE - Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "bdtx:LesseeOperatingLeaseNumberOfContracts", "reportCount": 1, "unique": true, "unitRef": "contract", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430413 - Disclosure - LEASES - Narrative (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails", "shortName": "LEASES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "bdtx:LesseeOperatingLeaseNumberOfContracts", "reportCount": 1, "unique": true, "unitRef": "contract", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ie6cd355ead2d42fda29fafd7e1c87f75_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431414 - Disclosure - LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails", "shortName": "LEASES - Summary of Lease Cost and Other Operating Lease Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ie6cd355ead2d42fda29fafd7e1c87f75_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ie6cd355ead2d42fda29fafd7e1c87f75_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ie6cd355ead2d42fda29fafd7e1c87f75_D20220401-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432415 - Disclosure - LEASES - Schedule of Future Minimum Lease Payments (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails", "shortName": "LEASES - Schedule of Future Minimum Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i92cccaa371b845e0bfdb95ca04f6497d_I20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2435416 - Disclosure - BENEFIT PLANS (Details)", "role": "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails", "shortName": "BENEFIT PLANS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "i4c350abdae9c4e0287f7f39a5dcd9f35_I20201231", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "role": "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "ic471377c282e40eb849df30a8d6d0f6a_D20210101-20210331", "decimals": "0", "lang": "en-US", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - NATURE OF BUSINESS AND BASIS OF PRESENTATION", "role": "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION", "shortName": "NATURE OF BUSINESS AND BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "role": "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - FAIR VALUE MEASUREMENTS", "role": "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "bdtx-20220630.htm", "contextRef": "id617f083480e431fab0dc51306944a6c_D20220101-20220630", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 37, "tag": { "bdtx_A2020EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Employee Stock Purchase Plan", "label": "2020 Employee Stock Purchase Plan [Member]", "terseLabel": "2020 ESPP" } } }, "localname": "A2020EmployeeStockPurchasePlanMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "bdtx_A2020StockOptionPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Stock Option Plan", "label": "2020 Stock Option Plan [Member]", "terseLabel": "2020 Stock Option Plan" } } }, "localname": "A2020StockOptionPlanMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "bdtx_AccruedContractResearchServiceFeesCurrent": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Contract Research Service Fees, Current", "label": "Accrued Contract Research Service Fees, Current", "terseLabel": "Contracted research services" } } }, "localname": "AccruedContractResearchServiceFeesCurrent", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "bdtx_DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Three", "terseLabel": "Fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleFairValueMaturityAllocatedAndSingleMaturityDateAfterYearOneThroughThree", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "bdtx_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) in Operating Lease Liabilities", "label": "Increase (Decrease) in Operating Lease Liabilities", "terseLabel": "Non-current operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bdtx_LeaseOtherInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease, Other Information [Abstract]", "label": "Lease, Other Information [Abstract]", "terseLabel": "Other Operating Lease Information" } } }, "localname": "LeaseOtherInformationAbstract", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "stringItemType" }, "bdtx_LesseeOperatingLeaseArea": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Area", "label": "Lessee, Operating Lease, Area", "terseLabel": "Area leased (square feet)" } } }, "localname": "LesseeOperatingLeaseArea", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "areaItemType" }, "bdtx_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, Payments, Due after Year Four", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "bdtx_LesseeOperatingLeaseNumberOfContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Number Of Contracts", "label": "Lessee, Operating Lease, Number Of Contracts", "terseLabel": "Number of leases" } } }, "localname": "LesseeOperatingLeaseNumberOfContracts", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "integerItemType" }, "bdtx_OpenMarketSaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Open Market Sale", "label": "Open Market Sale [Member]", "terseLabel": "Open Market Sale" } } }, "localname": "OpenMarketSaleMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "bdtx_OperatingLeaseOfficeAndLaboratorySpaceNYMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Office and Laboratory Space, NY", "label": "Operating Lease, Office and Laboratory Space, NY [Member]", "terseLabel": "Operating Lease, Office and Laboratory Space, NY" } } }, "localname": "OperatingLeaseOfficeAndLaboratorySpaceNYMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bdtx_OperatingLeasePrincipalOfficeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Principal Office, One", "label": "Operating Lease, Principal Office, One [Member]", "terseLabel": "Principal office, lease one" } } }, "localname": "OperatingLeasePrincipalOfficeOneMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bdtx_OperatingLeasePrincipalOfficeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Principal Office, Two", "label": "Operating Lease, Principal Office, Two [Member]", "terseLabel": "Principal office, lease two" } } }, "localname": "OperatingLeasePrincipalOfficeTwoMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "bdtx_OtherAwardTypeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Award Type", "label": "Other Award Type [Member]", "terseLabel": "Employee Stock Purchase Plan and Other" } } }, "localname": "OtherAwardTypeMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "bdtx_PerformanceRestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance Restricted Stock Units", "label": "Performance Restricted Stock Units [Member]", "terseLabel": "Performance Restricted Stock Units" } } }, "localname": "PerformanceRestrictedStockUnitsMember", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "bdtx_RentExpense": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rent Expense", "label": "Rent Expense", "terseLabel": "Noncash rent expense" } } }, "localname": "RentExpense", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bdtx_RightOfUseAssetDerecognizedTerminationOfLease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Right-of-Use Asset, Derecognized, Termination of Lease", "label": "Right-of-Use Asset, Derecognized, Termination of Lease", "terseLabel": "Right-of-use asset derecognized upon early lease termination" } } }, "localname": "RightOfUseAssetDerecognizedTerminationOfLease", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase of Authorized Shares, Percent of Common Stock Outstanding", "terseLabel": "Increase of authorized shares, percent of common stock outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseOfAuthorizedSharesPercentOfCommonStockOutstanding", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "percentItemType" }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Employee Subscription Amount", "terseLabel": "Maximum employee subscription amount" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionAmount", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "bdtx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Purchase Period", "terseLabel": "Award purchase period (in months)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePeriod", "nsuri": "http://www.blackdiamondtherapeutics.com/20220630", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r366" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r364" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "srt_MaximumMember": { "auth_ref": [ "r152", "r153", "r154", "r155", "r168", "r174", "r189", "r191", "r299", "r300", "r301", "r302", "r303", "r304", "r323", "r346", "r347", "r360", "r361" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r146", "r152", "r153", "r154", "r155", "r168", "r174", "r180", "r189", "r191", "r223", "r224", "r225", "r299", "r300", "r301", "r302", "r303", "r304", "r323", "r346", "r347", "r360", "r361" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r146", "r152", "r153", "r154", "r155", "r168", "r174", "r180", "r189", "r191", "r223", "r224", "r225", "r299", "r300", "r301", "r302", "r303", "r304", "r323", "r346", "r347", "r360", "r361" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r75", "r190" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r75", "r80", "r151", "r190" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r75", "r80", "r151", "r190", "r292" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r20", "r291" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Professional Fees, Current", "terseLabel": "Professional and consulting fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r8", "r142" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r15", "r29", "r30", "r31", "r338", "r352", "r353" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r28", "r31", "r37", "r38", "r39", "r67", "r68", "r69", "r248", "r288", "r348", "r349" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated other comprehensive income (loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r13", "r291" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r67", "r68", "r69", "r235", "r236", "r237", "r252" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r194", "r239", "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustment to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r228" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r10", "r64", "r103", "r105", "r109", "r127", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r245", "r249", "r262", "r289", "r291", "r327", "r337" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r19", "r64", "r127", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r245", "r249", "r262", "r289", "r291" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r255" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r118" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized Gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r119" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Unrealized Losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r116", "r134" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r112", "r117", "r134", "r329" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r114", "r134" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r197", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r217", "r218", "r220", "r221", "r222", "r223", "r224", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation and unaudited interim financial information" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r2", "r66", "r102" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "NATURE OF BUSINESS AND BASIS OF PRESENTATION" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r59", "r60", "r61" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchases of equipment included in accounts payable and accrued expenses" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r3", "r6", "r58" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents:" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r53", "r58", "r62" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Cash, cash equivalents and restricted cash, end of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]", "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r53", "r263" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "auth_ref": [ "r181", "r259" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r24", "r330", "r342" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note\u00a010)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r148", "r149", "r150", "r156", "r356" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r67", "r68", "r252" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r12", "r176" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r12", "r291" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock; $0.0001 par value; 500,000,000 shares authorized at June\u00a030, 2022 and December\u00a031, 2021; 36,315,737 shares issued and outstanding at June\u00a030, 2022 and 36,234,624 shares issued and outstanding at December\u00a031, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "auth_ref": [ "r178", "r179", "r192", "r241" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.", "label": "Compensation and Employee Benefit Plans [Text Block]", "terseLabel": "BENEFIT PLANS" } } }, "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANS" ], "xbrltype": "textBlockItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r33", "r35", "r36", "r41", "r332", "r344" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive loss:" } } }, "localname": "ComprehensiveIncomeNetOfTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r63", "r247" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in process" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "auth_ref": [ "r122", "r136", "r139" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Loss position fair value" } } }, "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of Marketable Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "terseLabel": "Employer contribution amount" } } }, "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Employer contribution, percent of each participant's salary" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer contribution, matching contribution percentage" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/BENEFITPLANSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r56", "r140" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r196", "r197", "r229", "r230", "r232", "r241" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r42", "r72", "r73", "r74", "r75", "r76", "r81", "r83", "r85", "r86", "r87", "r91", "r92", "r253", "r254", "r333", "r345" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share, basic (in dollars per share)", "verboseLabel": "Net loss per share, basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r42", "r72", "r73", "r74", "r75", "r76", "r83", "r85", "r86", "r87", "r91", "r92", "r253", "r254", "r333", "r345" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share, diluted (in dollars per share)", "verboseLabel": "Net loss per share, diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r88", "r89", "r90", "r93" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "NET LOSS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r22" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r231" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation cost, recognition period (in years)" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r231" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost, options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "Shares issuable under employee stock purchase plan" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Options to purchase common stock", "verboseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r37", "r38", "r39", "r67", "r68", "r69", "r71", "r77", "r79", "r94", "r128", "r176", "r177", "r235", "r236", "r237", "r243", "r244", "r252", "r264", "r265", "r266", "r267", "r268", "r269", "r288", "r348", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r255", "r256", "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r169", "r171", "r172", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r256", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r255", "r256", "r257", "r258", "r261" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r259" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r169", "r181", "r182", "r187", "r188", "r256", "r296" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r169", "r171", "r172", "r181", "r182", "r187", "r188", "r256", "r297" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r169", "r171", "r172", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r256", "r298" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level\u00a03" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r169", "r171", "r172", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r296", "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r259", "r261" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r120", "r121", "r124", "r125", "r126", "r129", "r130", "r131", "r132", "r133", "r135", "r137", "r138", "r139", "r170", "r175", "r251", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r368", "r369", "r370", "r371", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r56" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedTerseLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnTerminationOfLease": { "auth_ref": [ "r270" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.", "label": "Gain (Loss) on Termination of Lease", "terseLabel": "Gain on lease termination" } } }, "localname": "GainLossOnTerminationOfLease", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r44" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r144", "r147" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "auth_ref": [ "r55" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.", "label": "Increase (Decrease) in Accounts Payable, Trade", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayableTrade", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r55" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in current assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r55" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other non-current assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r55" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Common stock" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": { "auth_ref": [ "r46" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.", "label": "Investment Income, Net, Amortization of Discount and Premium", "negatedTerseLabel": "Amortization of premium on investments" } } }, "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNonoperating": { "auth_ref": [ "r45" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income from investments (for example, dividends) not considered a component of the entity's core operations.", "label": "Investment Income, Nonoperating", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeNonoperating", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r255" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Investments:" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r123", "r326", "r335", "r354", "r375" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "INVESTMENTS" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseContractualTermAxis": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Information by contractual term of lease arrangement.", "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term [Axis]" } } }, "localname": "LeaseContractualTermAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseContractualTermDomain": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Contractual term of lease arrangement.", "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term [Domain]" } } }, "localname": "LeaseContractualTermDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r284", "r286" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Lease Cost" } } }, "localname": "LeaseCostAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Summary of Lease Cost and Other Operating Lease Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r285" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Future Minimum Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r285" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r285" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r285" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r285" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r285" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r285" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2022 (excluding the six months ended June\u00a030, 2022)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r285" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Lease term, optional extension (in years)" } } }, "localname": "LesseeOperatingLeaseRenewalTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Lease term (in years)" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r287" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LettersOfCreditOutstandingAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.", "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letter of credit outstanding" } } }, "localname": "LettersOfCreditOutstandingAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r21", "r64", "r106", "r127", "r157", "r158", "r159", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r246", "r249", "r250", "r262", "r289", "r290" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r18", "r64", "r127", "r262", "r291", "r328", "r340" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r23", "r64", "r127", "r157", "r158", "r159", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r246", "r249", "r250", "r262", "r289", "r290", "r291" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r53" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r53" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r53", "r54", "r57" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r32", "r34", "r39", "r40", "r57", "r64", "r70", "r72", "r73", "r74", "r75", "r78", "r79", "r84", "r103", "r104", "r107", "r108", "r110", "r127", "r157", "r158", "r159", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r254", "r262", "r331", "r343" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently issued accounting pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r45" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "auth_ref": [ "r200" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.", "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Schedule of Restricted Stock Activity" } } }, "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Computer and office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r103", "r104", "r107", "r108", "r110" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r277", "r286" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]", "terseLabel": "ASC 842" } } }, "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r272" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Total lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESScheduleofFutureMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r272" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current portion of operating lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.", "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]" } } }, "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESDetails" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r272" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r274", "r280" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of lease liability" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r271" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r283", "r286" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r282", "r286" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r9" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other non-current assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax": { "auth_ref": [ "r26", "r27" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), before Adjustment, after Tax", "terseLabel": "Change in unrealized loss on investments", "verboseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeReclassificationAdjustmentsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "terseLabel": "Other comprehensive income:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other income (expense):" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r47" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "auth_ref": [ "r115" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-Sale", "terseLabel": "Impairment of fair value assets" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r51" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "negatedTerseLabel": "Purchases of investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r50" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r197", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r217", "r218", "r220", "r221", "r222", "r223", "r224", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r197", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r217", "r218", "r220", "r221", "r222", "r223", "r224", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r11", "r173" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r11", "r173" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r11", "r291" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized at June\u00a030, 2022 and December\u00a031, 2021; no shares issued or outstanding at June\u00a030, 2022 and December\u00a031, 2021" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r19" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r52", "r234" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from exercise of common stock options and ESPP" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "auth_ref": [ "r48", "r49", "r113" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "terseLabel": "Proceeds from sales and maturities of investments" } } }, "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Property, Plant and Equipment, Type [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r145", "r357", "r358", "r359" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENT" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r7", "r141" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r143", "r291", "r336", "r341" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total Property and Equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Property, Plant and Equipment, Type [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r242", "r324", "r362" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r9", "r62", "r355" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r14", "r177", "r291", "r339", "r351", "r353" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r67", "r68", "r69", "r71", "r77", "r79", "r128", "r235", "r236", "r237", "r243", "r244", "r252", "r348", "r350" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "domainItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r281", "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligation" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Proceeds from stock issuance, net" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/ACCRUEDEXPENSESANDOTHERCURRENTLIABILITIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Net Loss per Share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r87" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Computation of Net Loss per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r227", "r238" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r255", "r256" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/PROPERTYANDEQUIPMENTDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r193", "r195", "r197", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r217", "r218", "r220", "r221", "r222", "r223", "r224", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r201", "r216", "r219" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r55" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r213" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant-date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r210", "r211" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested restricted common stock, ending balance (in shares)", "periodStartLabel": "Unvested restricted common stock, beginning balance (in shares)", "terseLabel": "Units outstanding (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number\u00a0of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r210", "r211" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested restricted common stock, ending balance (in dollars per share)", "periodStartLabel": "Unvested restricted common stock, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted average grant\u00a0date fair value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Fair value of units vested" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r214" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Maximum employee subscription rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted Average Remaining Life and Intrinsic Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Options exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedTerseLabel": "Canceled or forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r205" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "terseLabel": "Cancelled or forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Options outstanding, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r202", "r203" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, ending balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r202", "r203" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, ending balance (in dollars per share)", "periodStartLabel": "Outstanding, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r220" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "terseLabel": "Options vested or expected to vest, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options vested or expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Options vested or expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Shares issued under share-based compensation plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r197", "r198", "r199", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r217", "r218", "r220", "r221", "r222", "r223", "r224", "r225", "r226" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockActivityDetails", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r207" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r206" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Options exercisable, intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Options exercisable, remaining life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options outstanding, remaining life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r220" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Options vested or expected to vest, remaining life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Maximum percent of fair market value of common stock" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r278", "r286" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-Term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r25", "r37", "r38", "r39", "r67", "r68", "r69", "r71", "r77", "r79", "r94", "r128", "r176", "r177", "r235", "r236", "r237", "r243", "r244", "r252", "r264", "r265", "r266", "r267", "r268", "r269", "r288", "r348", "r349", "r350" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r67", "r68", "r69", "r94", "r325" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r11", "r12", "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock related to ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "auth_ref": [ "r11", "r12", "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r11", "r12", "r176", "r177" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r11", "r12", "r176", "r177", "r207" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedTerseLabel": "Exercised (in shares)", "verboseLabel": "Exercise of common stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited", "http://www.blackdiamondtherapeutics.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r11", "r12", "r176", "r177" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock related to ESPP" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r25", "r176", "r177" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of common stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r12", "r16", "r17", "r64", "r111", "r127", "r262", "r291" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders' equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited", "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofStockholdersEquityUnaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedBalanceSheetsUnaudited" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NATUREOFBUSINESSANDBASISOFPRESENTATIONDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r120", "r121", "r124", "r125", "r126", "r170", "r175", "r251", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r368", "r369", "r370", "r371", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r65", "r181", "r334" ], "lang": { "en-us": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. Government agencies" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueAssetsandLiabilitiesMeasuredonRecurringBasisDetails", "http://www.blackdiamondtherapeutics.com/role/INVESTMENTSScheduleofMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r95", "r96", "r97", "r98", "r99", "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r279", "r286" ], "calculation": { "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/LEASESSummaryofLeaseCostandOtherOperatingLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrants to purchase common stock" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREScheduleofAntidilutiveSecuritiesExcludedfromComputationofNetLossperShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r82", "r87" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average common shares outstanding, diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r81", "r87" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average common shares outstanding, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.blackdiamondtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLossUnaudited", "http://www.blackdiamondtherapeutics.com/role/NETLOSSPERSHAREComputationofNetLossperShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563" }, "r123": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r178": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "710", "URI": "https://asc.fasb.org/topic&trid=2127225" }, "r179": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "712", "URI": "https://asc.fasb.org/topic&trid=2197446" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r192": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org/topic&trid=2235017" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r2": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r241": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "40", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r287": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/subtopic&trid=77888251" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r326": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803" }, "r335": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r363": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r364": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r365": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r366": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r367": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r368": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r369": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r370": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)" }, "r371": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)" }, "r372": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)" }, "r373": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)" }, "r374": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)" }, "r375": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403" }, "r376": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r377": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" } }, "version": "2.1" } ZIP 60 0001701541-22-000029-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001701541-22-000029-xbrl.zip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Ύ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�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end